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L-ORNITHINE PRODUCTION IN EUKARYOTIC CELLS
TECHNICAL FIELD OF THE INVENTION
The present invention relates to the development of genetically engineered microorganisms that can produce
L-ornithine and its derivatives. More specifically the invention relates to the production of L-ornithine, which can,
for instance, be used as food additive using genetically engineered eukaryotic cells. Such L-ornithine producing
eukaryotic cells, for instance yeast cells, can also be directly used for baking, brewing, or making other food
products. In addition, other new chemicals using L-ornithine as precursors in the cell can also be produced when
said L-ornithine producing eukaryotic cells are subject to further genetic modifications. These chemicals include
but not limited to L-arginine, L- citrulline, putrescine, spermidine, spermine, agmatine and tropane alkaloids, etc.
BACKGROUND OF THE INVENTION
L-ornithine, the intermediate of L-arginine biosynthesis, has already been widely used as a dietary
supplement, as it is known to be beneficial for the treatment of wound healing and liver disease. Furthermore, it
is also the precursor of bulk chemicals such as putrescine, an important diamine used as a nylon monomer, and
natural products such as tropane alkaloids, which are used as parasympatholytics for competitively antagonizing
acetylcholine.
L-ornithine is nowadays prepared by various processes, encompassing chemical synthesis and enzymatic
catalysis. For instance, EP0464325A2 discloses an enzymic conversion process for the preparation of salts of L-
ornithine from L-arginine in the presence of the enzyme L-arginase (EC 3.5.3.1.) extracted from animal liver. To
reduce the cost of the enzyme, a whole-cell biotransformation system for the conversion of L-arginine to L-
ornithine was also developed by constructing a recombinant Escherichia coli with overexpressed arginase (EC
3.5.3.1) encoding gene ARG from the bovine liver (Zhan et al. 2013). However, said whole-cell biotransformation
system always has the problem of cell permeability, and addition of permeability reagent may lead to subsequent
product separation problems. One idea has been to screen for a thermophilic enzyme, higher operation
temperature could be used to improve the permeability of the recombinant cells. Arginase {ARG) from Bacillus
caldovelox was found to be a potential thermophilic candidate (Patchett et al. 1991). Recently, the recombinant
E. coli with B. caldovelox ARG gene was constructed, leading to an efficient and simple enzymatic process for
the environment-friendly synthesis of L-ornithine from L-arginine (Song et al. 2014).
However, these methods either suffer from issues of expensive substrates, poor enantiopure purity or are
environmental unfriendly.
Some L-citrulline or L-arginine auxotroph bacteria belong to the genus Brevibacterium, the genus
Corynebacterium, the genus Bacillus and the genus Arthrobacter are known to produce L-ornithine. In addition,
variants of said L-ornithine producing bacteria having resistance to arginine analogues and/or 2-thiazolealanine
and/or sulfaguanidine and/or 2-fl uoropyruvic acid and/or microphenolic acid and/or ornithinol are said to have
better L-ornithine producing performance. Metabolic engineering frameworks, which offer the ability to leverage
the advantages of biocatalysts (e.g. precision, specificity) and tailor the carbon flow of microbes, have enabled
construction of platform cell factories for producing amino acids. Recent advantages in the said metabolic
engineering also lead to the strain construction for L-ornithine production (Hwang and Cho 201 2; Hwang and Cho
2014; Hwang et al. 2008; Jiang et al. 2013a; Jiang et al. 2013b). For instance, WO 2012008809 A2 discloses a
strategy to give the L-ornithine production at a high yield rate and with high efficiency by the fine-turning of
gluconate kinase (GntK) in Corynebacterium. In another disclose, US 8741608 B2 suggests thatoverexpressing
of L-ornithine exporter is an efficient strategy to further improve L-ornithine titers. US 20140051132 A 1 also
discloses an invention where NCgl_2067-NCgl_2065 operon in Corynebacterium is/are attenuated lead to the
improved production of L-amino acids belonging to L-glutamate family which includes L-ornithine. NCgl_2067-
NCgl_2065 operon was suggested to encode negative regulators which directly controls expression of the related
genes in the L-amino acids synthesis belong to L-glutamate.
However, one of the main drawbacks of L-ornithine production in bacterial strains is the phage contamination
issues which often result in substantial economic losses. Thus, there is a need for better microbial strategies for
the production of L-ornithine, putrescine, spermidine, spermine and other chemicals using these compounds as
a precursor
SUMMARY OF THE INVENTION
Thus it is an object of the present disclose to provide an improved eukaryotic cell factory, such yeast cell
factory that can be used for fermentation based production of L-ornithine. The L-ornithine synthesis pathway, and
even the central metabolism in the said cell factory are harnessed to manage the said challenges.
An aspect of the embodiments relates to a eukaryotic cell capable of producing L-ornithine. The eukaryotic
cell is genetically modified for attenuated activity of an ornithine carbamyoltransferase.
Another aspect of the embodiments relates to a eukaryotic cell capable of producing L-ornithine. The
eukaryotic cell is genetically modified for enhanced L-ornithine biosynthesis from a-ketoglutarate.
A further aspect of the embodiments relates to a eukaryotic cell capable of producing L-ornithine. The
eukaryotic cell is genetically modified for enhanced a-ketoglutarate biosynthesis.
Yet another aspect of the embodiments relates to a process for production of L-ornithine. The process
comprising cultivating a eukaryotic cell according to the embodiments in the presence of a carbon source.
The eukaryotic cells of the embodiments can be further genetically modified for the production of polyamines.
A further aspect of the embodiments relates to a process for production of a polyamine selected from the group
consisting of putrescine, spermidine and spermine. The process comprising cultivating a eukaryotic cell according
to the embodiments in the presence of a carbon source.
The successful proof of concept production of L-ornithine with S. cerevisiae in the present disclose
represents the first systematics case implementation to produce amino acids in eukaryotic microbes, which
demonstrated the potential to use eukaryotic microbes as the cell factory to produce amino acid or even other
amino acid derived chemicals.
According to the present invention microbes can be further engineered to produce L-ornithine-derived
products, such as the polyamines putrescine, spermidine and spermine, as well as the arginine-derivative
agmatine, which have a variety of industrial applications. This includes overexpression of native and heterologous
steps in the biosynthesis of these compounds, as well as elimination of competitive steps. Furthermore, the
cellular transport systems are manipulated to allow export of these compounds into the media. We also present
several gene targets that can be manipulated in order to allow high tolerance to these compounds when
synthesized at large quantities.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1. L-arginine leaky auxotroph enables L-ornithine overproduction (a) The attenuation ARG was
implemented by replacing the original promoter of ARG3 with the HXT1 or KEX2 promoter {P XTI-
ARG3 and P AR G respectively). Dashed arrows represent multiple reaction steps (b) The transcriptional
attenuation of Arg3p and knockout of L-ornithine potential consumption step (Car2p) led L-ornithine
overproduction. Black filled circle indicates the molecular implementation is included in the strain under test (c)
The transcriptional attenuation of Arg3p decreased the intracellular L-arginine pool. All the strains were cultivated
for 72 h in Delft medium. All data are presented as the mean ± s.d. (n>3).
FIG.2: Improved L-ornithine production by optimizing the flux from a-ketoglutarate to L-ornithine 'acetylated
derivatives cycle'. Three strategies were proposed to eliminate the obstacles in the Module 2 as follows: (a)
Strategy (i), intrinsic pathways including intracellular trafficking steps of Module 2 was strengthened; (b) Strategy
(ii), L-glutamate dehydrogenase reaction was proposed to be re-localized to the mitochondria to bypass the
potential intracellular trafficking of a-ketoglutarate and (c). Strategy (iii), L-glutamate and chimeric L-ornithine
'acetylated derivatives cycle' from bacteria was re-localized to cytosol to bypass the potential obstacles of
intracellular metabolites' trafficking (d) Pathway variants of Strategy (i) and Strategy (iii) in Module 2 enable
substantial increase of L-ornithine titers. All the strains were cultivated for 72 h in definite Delft medium. All data
are presented as the mean ± s.d. (n>3).
FIG.3: L-ornithine production improved through strategies to reduce the 'Crabtree effect'. Different strategies
to reduce the 'Crabtree effect' on the purpose of improve the carbon channeling from carbon substrate L-glucose
to product L-ornithine were proposed. Abbreviation: K, citric acid cycle; 0 , L-ornithine 'acetylated derivatives
cycle'; EMP, glycolysis pathway; PYC, pyruvate; EOH, ethanol; ACT, aldehyde; GLC, glucose; a-KG, a-
ketoglutarate; MPC, mitochondrial pyruvate carrier; Od p, proposed mitochondria a-ketoglutarate transporter
protein; Ort1 p, mitochondria L-ornithine transporter; Ag p, mitochondria L-glutamate transporter; MTH1-AT,
truncated version of MTH1, AOX, NADH alternative oxidase; Q, ubiquinone; Ndil p, NADH: ubiquinone
oxidoreductase. Respiratory chain (complexes lll-IV) is shown as a rectangle, and ATP synthase (complex V) as
a square (a) Strategy (i), directly overexpresses the TCA cycle enzymes including the mutated vision of Pda1 p
which was suggested to improve the TCA cycle flux. The circled + and - symbols denote the reactions/pathways
that increased oxidative TCA cycle activity is expected to accelerate or slow down (b) Strategy (ii), overexpress
the NADH alternative oxidase from H. anomala {HaAOXI) to increase the capacity of the respiration chain which
was suggested could reduce the 'Crabtree effect'. The circled + and - symbols denote the reactions/pathways
that overexpression of AOX and Ndil p is expected to accelerate or slow down (c) Strategy (iii), control the
glucose uptake rates by overexpression the truncated Mthl p from which the dephosphorylating site was removed.
The circled + and - symbols denote the reactions/pathways that overexpression of MTH1-AT is expected to
accelerate or slow down (d) Strains with variants pathways in Module 3 led to increase production of L-ornithine.
All the strains were cultivated for 72 h in definite Delft medium. All data are presented as the mean ± s.d. (n>3)
(e) Physiological characterization of strain harboring truncated MTH1-ATand the control. µ (Ιν 1) , ΓΕΟΗ [g ethanol
(g DCW)- h-1] and r i [g glucose (g DCW)- lv 1] are shown. All values were calculated in batch culture on glucose
during exponential growth phase, identified by the linear relationship between the natural logarithm of culture time
and biomass. All data are presented as the mean ± s.d. (n>3). (f) Physiological characterization of strain harboring
truncated MTH1-AT nd the control. Yx/s [(g DCW) (g glucose) 1] , YORN/S [mg L-ornithine (g glucose) 1] and YEOH/S
[g ethanol (g glucose) 1] are shown. All values were calculated in batch culture on glucose during exponential
growth phase, identified by the linear relationship between the natural logarithm of culture time and biomass. All
data are presented as the mean ± s.d. (n>3).
FIG.4: Fed-batch fermentation of engineered strain in 3-I bioreactor. Time course profile of DCW (grey line)
and L-ornithine (black line) of strain M 1dM2qM3a were shown.
FIG.5: Qualitative verification of L-ornithine produced by proof of concept strain with GC-MS. (a) Gas
chromatogram of L-ornithine (retention time 29.75 min). (b) High resolution mass spectrometry of L-ornithine.
FIG.6: RT-PCR indicated significant changes were in strains producing L-ornithine and the control strain.
The comparisons are M 1c vs. control, M 1cM2r vs. control and M 1cM2g vs. control. The grey-scale key represents
log2 [fold change], untextured grey represents up-regulation and dotted-grey represents down-regulation. The
intensity of the grey colour correlates with the fold-change.
FIG.7: Proposed underline mechanisms by which the L-ornithine 'acetylated derivatives cycle' flux was
boosted when Arg3p was attenuated.
FIG.8: The effect of truncated Gcn4p overexpression on L-ornithine titers. All the strains were cultivated for
72 h in definite Delft medium. All data are presented as the mean ± s.d. (n>3).
FIG.9: The single overexpression of related genes in the L-ornithine 'acetylated derivatives cycle' showed no
substantial effect to increase the L-ornithine titers. Black filled circle indicates the molecular implementation is
included in the strain under test. All the strains were cultivated for 72 h in definite Delft medium. All data are
presented as the mean ± s.d. (n>3).
FIG.10: The effect of 0DC1 overexpression of L-ornithine titers in both GDH1 and GDH3 overexpression
strain. All the strains were cultivated for 72 h in definite Delft medium. All data are presented as the mean ± s.d.
(n>3).
FIG.11: The mitochondria targeting of GDH1 and GDH2 gave substantial decrease to L-ornithine titers. All
the strains were cultivated for 72 h in definite Delft medium. All data are presented as the mean ± s.d. (n>3).
FIG. 12: The cytosolic L-ornithine synthesis pathway was functional verified by complementary test. While
the control strain could not grow in the medium without L-arginine, the strain harboring the cytosolic pathway
restored the ability to grow on L-arginine negative medium. Control represents Strain B0166A (p423GPD) and
G04 represents strain B0166A (0RT1). The overnight cultured cells were diluted to OD600 of 1, and 5µ Ι aliquots
of dilutions from 10 to1 0 6 were spotted on the corresponding plates.
FIG.13: The KGD2 knock-down gave L-ornithine titers decrease. All the strains were cultivated for 72 h in
definite Delft medium. All data are presented as the mean ± s.d. (n>3).
FIG.14: Overview of pathway leading to ornithine derivatives.
FIG. 15: Putrescine production in engineered yeast strains with or without an ornithine module. The ornithine
module includes pKEX2-ARG3, Acar2, GDH1, 0RT1, AGC1 and the cytosolic ornithine synthetic pathway in the
plasmid G04. Further engineering for putrescine production includes deletion of 0AZ1 and overexpression of
SPE1. Both intra- and extra-cellular levels of putrescine were quantified.
FIG. 16: Spermidine production in engineered yeast strains. Modification to the ornithine metabolism include
pKEX2-ARG3, Acar2, GDH1, 0RT1, AGC1 and the cytosolic ornithine synthetic pathway in the plasmid G04.
Further engineering for spermidine production includes deletion of 0AZ1 and overexpression of SPE1 , SPE2 and
SPE3.
DETAILED DESCRIPTION
Several unique features of Baker's yeast S. cerevisiae, including its robustness, GRAS (generally recognized
as safe) status, excellent availability of molecular biology tools, wide use in industry, including large scale
bioethanol production, and the more efficient ability to express complex enzymes such as cytochrome P450-
containing enzymes, make it an attractive chasis host for production various chemicals. Furthermore, as S.
cerevisiae is also widely used in brewing and baking industries, the L-ornithine producing yeast could represent
a plug and play solution for the production of L-ornithine containing drinks and/or baking products or even other
functional food products.
L-arginine biosynthesis is known for its compartmentalization in metabolism where L-ornithine, the precursor
of L-arginine is synthesized in the mitochondria using L-glutamate as substrate which is produced in the cytoplasm.
After transport to the cytoplasm, L-ornithine is converted to L-arginine after three consecutive steps. In addition,
a-ketoglutarate, the precursor of L-glutamate is one of the intermediates of TCA cycle, the flux of which is limited
by the so called 'Crabtree effect' leading to the formation of ethanol as main byproduct. It is obvious that
engineering S. cerevisiae to accumulate amino acids including L-ornithine remains a daunting task.
According to the above mentioned characteristics of L-ornithine metabolism, there are at least four
challenges in constructing an L-ornithine over-producing yeast strain: (i) how to tune more metabolic flux stop at
L-ornithine rather than toward L-arginine biosynthesis without incapacitating the ability of L-arginine synthesis, as
sufficient L-arginine is necessary for cell growth; (ii) how to balance and coordinate the corresponding pathways
and enzymes in different subcellular organelles, as pathway perturbation could create a substantial bottleneck
due to membranes transportation of intermediates and these intermediates will be redirect to competing pathways;
(iii) how to increase the supply of the precursor a-ketoglutarate, as 'Crabtree effect' will limit the TCA cycle
efficiency for α-ketoglutarate biosynthesis during normal batch fermentation with sufficient glucose; (iv) the total
pathway optimization calls for intensive perturbations to the related pathways. How to implement the desired
engineering strategies efficiently is yet to be demonstrated.
The invention herein relies, unless otherwise indicated, on the use of conventional techniques of metabolic
engineering, fermentation engineering, synthetic biology, biochemistry, molecular biology, cell biology,
microbiology and recombinant DNA technology.
To facilitate understanding of the invention, a number of terms are defined below.
As used herein, the term "modified" refers to a host organism that has been modified to increase production
of L-ornithine, putrescine, spermidine, spermine or agmatine, as compared with an otherwise identical host
organism that has not been so modified. In principle, such "modification" in accordance with the present disclosure
may comprise any physiological, genetic, chemical, or other modification that appropriately alters production of
these compounds production in a host organism as compared with such production in an otherwise identical
organism which is not subject to the said modification. In most of the embodiments, however, the modification will
comprise a genetic modification. In certain embodiments, as described herein, the modification comprises
introducing into a host cell, and particularly into a host cell which is reduced or negative for ornithine
carbamoyltransferase activity. In some embodiments, a modification comprises at least one physiological,
chemical, genetic, or other modification; in other embodiments, a modification comprises more than one chemical,
genetic, physiological, or other modification. In certain aspects where more than one modification is made use of,
such modifications can include any combinations of physiological, genetic, chemical, or other modification (e.g.,
one or more genetic, chemical and/or physiological modification(s)). Genetic modifications which boost the activity
of a polypeptide include, but are not limited to: introducing one or more copies of a gene encoding the polypeptide
(which may distinguish from any gene already present in the host cell encoding a polypeptide having the same
activity); altering a gene present in the cell to increase transcription or translation of the gene (e.g., altering, adding
additional sequence to, replacement of one or more nucleotides, deleting sequence from, or swapping for example,
regulatory, a promoter or other sequence); and altering the sequence (e.g. non-coding or coding) of a gene
encoding the polypeptide to boost activity (e.g., by increasing enzyme activity, decrease feedback inhibition,
targeting a specific subcellular location, boost mRNA stability, boost protein stability). Genetic modifications that
reduce activity of a polypeptide include, but are not limited to: deleting a portion or all of a gene encoding the
polypeptide; inserting a nucleic acid sequence which disrupts a gene encoding the polypeptide; changing a gene
present in the cell to reduce transcription or translation of the gene or stability of the mRNA or polypeptide encoded
by the gene (for example, by adding additional sequence to, altering, deleting sequence from, replacement of one
or more nucleotides, or swapping for example, replacement of one or more nucleotides, a promoter, regulatory or
other sequence).
As used herein, the term "open reading frame (ORF)" refers to a region of RNA or DNA encoding polypeptide,
a peptide, or protein.
As used herein, the term "recombinant" means that a particular nucleic acid (RNA or DNA) is the product of
various combinations of restriction, cloning, and/or ligation steps resulting in constructs with structural non-coding
or -coding sequences different from endogenous nucleic acids found in the systems of natural.
As used herein, "recombinant eukaryotic cells" according to the present disclose is defined as cells which
contain additional copies or copy of an endogenous nucleic acid sequence or are transformed or genetically
modified with polypeptide or a nucleotide sequence that does not naturally occur in the eukaryotic cells. The wild-
type eukaryotic cells are defined as the parental cells of the recombinant eukaryotic cells, as used herein.
As used herein, "recombinant prokaryotic cells" according to the present disclose is defined as cells which
contain additional copies or copy of an endogenous nucleic acid sequence or are transformed or genetically
modified with polypeptide or a nucleotide sequence that does not naturally occur in the prokaryotic cells. The wild-
type prokaryotic cells are defined as the parental cells of the recombinant prokaryotic cells, as used herein.
As used herein, the term "endogenous" when used with respect to a nucleic acid (RNA or DNA) or protein
refers to a protein or a nucleic acid which occurs naturally as part of the cell, organism, genome or RNA or DNA
sequence where it is present.
As used herein, the term "heterologous" when used with respect to a nucleic acid (RNA or DNA) or protein
refers to a protein or a nucleic acid which occurs non-naturally as part of the cell, organism, genome or RNA or
DNA sequence where it is present. Heterologous proteins or nucleic acids are not endogenous to the cell where
it is introduced, but have been obtained from synthetically produced or one of another cells.
As used herein, the term "gene" indicates to a nucleic acid sequence which contains a template for a nucleic
acid polymerase (in eukaryotes, RNA polymerase II). Genes are transcribed into mRNAs which are then translated
into proteins.
As used herein, the term "genome" encompasses both the plasmids and chromosomes in a host cell. For
instance, encoding nucleic acids of the present disclosure which are introduced into host cells can be portion of
the genome whether they are chromosomally integrated or plasmids-localized, i.e. present in plasmids.
As used herein, the term "nucleic acid" refers to a ribonucleotide polymer or unless otherwise indicated, the
term includes reference to the complementary sequence and the specified sequence thereof.
As used herein, the terms "peptide", "polypeptide", and "protein" are used interchangeably to indicate to a
polymer of amino acid residues. The terms "peptide", "polypeptide" and "protein" also includes modifications
including, but not limited to, lipid attachment, glycosylation, glycosylation, sulfation, hydroxylation, γ-carboxylation
of L-glutamic acid residues and ADP-ribosylation.
As used herein, the term "enzyme" is defined as a protein which catalyses a chemical or a biochemical
reaction in a cell. Usually, according to the present invention, the nucleotide sequence encoding an enzyme is
operably linked to a nucleotide sequence (promoter) that causes sufficient expression of the corresponding gene
in the eukaryotic cell to confer to the cell the ability to produce L-ornithine.
As used herein, the term "promoter" refers to a nucleic acid sequence which has functions to control the
transcription of one or more genes, which is located upstream with respect to the direction of transcription of the
transcription initiation site of the gene. Suitable promoters in this context include both constitutive and inducible
natural promoters as well as engineered promoters, which are well known to the person skilled in the art. Suitable
promoters in eukaryotic host cells may be PDC, GPD1, TEF1, PGK1 and TDH. Other suitable promoters include
HIS3, CYC1, ADH1, PGL, GAPDH, ADC1, URA3, TRP1, LEU2, ΤΡΙ, ΑΟΧΙ and EN01.
As used herein, the term "terminator" is functional in the eukaryotic cell used in the present invention. Natural
genes of the host cell are the preferred terminators source.
As used herein, the term "overexpression" refers to increasing the number of copies of a desired nucleic acid
sequence. Normally, overexpression leads to an increased level of activity of an enzyme and/or proteins, and/or
to an increased level of activity in a desirable location (e.g., in the cytosol or mitochondria). There are a lot of
strategies available in the art for overexpression of special nucleotide sequences encoding enzymes and/or
proteins in a eukaryotic cell. Particularly, a nucleotide sequence encoding an enzyme/protein may be
overexpressed by increasing the copy number of the gene coding for the enzyme/protein in the cell, e.g. by
integrating additional copies of the gene in the cell's genome, from an episomal multicopy expression vector, by
expressing the gene from a centromeric vector, or by introducing an (episomal) expression vector that comprises
multiple copies of the gene. Preferably, overexpression of the enzyme/protein according to the disclosure is
obtained with a constitutive strong promoter.
The term "overproducing" is used herein in reference to the production of L-ornithine in a host cell and
indicates that the host cell is producing more of L-ornithine, putrescine, spermidine, spermine or other compounds
as disclosed herein by virtue of the introduction of nucleic acid sequences which encode different polypeptides
involved in the host cell's metabolic pathways or as a result of other modifications as compared with the
unmodified host cell or wild-type cell.
As used herein, the term "Crabtree effect" refers to the phenomenon whereby the yeast, S. cerevisiae,
produces ethanol in high external glucose concentrations and aerobic conditions rather than producing biomass
via the tricarboxylic acid (TCA) cycle, which is the common process occurring aerobically in most yeasts e.g.
Kluyveromyces spp.
As used herein the term "vector" is defined as a linear or circular DNA molecule comprising a polynucleotide
encoding a polypeptide of the invention, and which is operably linked to additional nucleotides that ensure its
expression.
As used herein, sequence identity refers to sequence similarity between two nucleotide sequences or two
peptide or protein sequences. The similarity is determined by sequence alignment to determine the structural
and/or functional relationships between the sequences.
In certain embodiments, the present disclosure relates to a modified eukaryotic cell, preferably, the eukaryotic
cell is yeast cell, wherein the yeast cell can overproduce L-ornithine. Said overproduction of L-ornithine is obtained
in the first place by the down-regulation or attenuation of specially selected genes, wherein said genes encode
enzymes involved in the L-ornithine and/or polyamine consumption and/or degradation pathways. Further L-
ornithine production ability is improved by down-regulation, attenuation, deletion or overexpression of specially
selected genes, wherein said genes encode enzymes and/or proteins involved in the L-ornithine 'acetylated
derivatives cycle', L-glutamate synthesis pathways, subcellular trafficking, TCA cycle, pyruvate carboxylation
pathway, respiratory electron-transport chain, and the carbon subtracts assimilation machinery.
Preferably, the yeast to be modified can be selected from any known genus and species of yeast. In one
embodiment, the yeast genus can be Saccharomyces, Kluyveromyces, Zygosaccharomyces, Candida,
Hansenula, Torulopsis, Kloeckera, Pichia, Schizosaccharomyces, Trigonopsis, Brettanomyces, Debaromyces,
Nadsonia, Lipomyces, Cryptococcus, Aureobasidium, Trichosporon, Lipomyces, Rhodotorula, Yarrowia, Phaffia,
or Schwanniomyces, among others. In a further embodiment, the yeast can be Saccharomyces, Yarrowia,
Zygosaccharomyces, Kluyveromyces Pichia spp. In yet a further embodiment, the yeast can
be Saccharomyces cerevisiae, Saccharomyces boulardii, Zygosaccharomyces bailii, Kluyveromyces
lactis, and Yarrowia lipolytica. Saccharomyces cerevisiae is commonly used yeast in industrial processes, but the
disclosure is not limited thereto. Other yeast species useful in the present disclosure include but are not limited
to Schizosaccharomyces pombe, Hansenula anomala, Candida sphaerica, and Schizosaccharomyces
malidevorans.
In one embodiment the prokaryotic cell can be a bacterial cell or archaeal cell. The recombinant bacterial
cell could be gram positive or gram negative bacteria. The bacteria may also be photosynthetic bacteria e.g.
cyanobacteria). The bacteria can either be Gram-negative or Gram-positive. The genera of Gram negative
bacteria include, for example, Neisseria, Spirillum, Pasieureiia, Brucella, Yersinia, Franciseiia, Haemophilus,
Bordeteiia, Escherichia, Salmonella, Shigella, Klebsiella, Proteus, Vibrio, Pseudomonas, Bacteroides,
Acetobacter, Aerobacter, Agrobacierium, Azotobacter, Spirilla, Serratia, Vibrio, Rhizobium, Chlamydia, Rickettsia,
Treponema, and Fusobacterium. The genera of Gram positive bacteria include, for example, Actinomyces,
Bacillus, Clostridium, Corynebactenum, Erysipeiothrix, Lactobacillus, Listeria, Mycobacterium, Myxococcus,
Nocardia, Staphylococcus, Streptococcus, and Streptomyces.
In some embodiments, the present disclose relates to a modified yeast cell, wherein the activity of the L-
ornithine consumption and/or degradation pathway of the yeast cell was reduced. In one preferred embodiment,
the yeast cell is S. cerevisiae. In one preferred embodiment, the activity of ornithine carbamoyltransferase in S.
cerevisiae is reduced. In one preferred embodiment, the activity of ornithine carbamoyltransferase in S. cerevisiae
is reduced by down-regulation, attenuation or deletion the ornithine carbamoyltransferase encoding gene, wherein
the said gene is ARG3. The attenuation of objective gene can be achieved by known methods in the art. In one
preferred embodiment, the attenuation of ARG3 is achieved by replaced the promoter region of ARG3 with weak
constitutive promoter, for instance the promoter of KEX2. It was found that the attenuation of the ARG3 by the
promoter replacement strategy led to the production of L-ornithine which would not achieve with the wild-type
strain which has native ARG3 promoter.
In one preferred embodiment, the reduced L-ornithine degradation activity is achieved by reducing the activity
of L-ornithine transaminase (OTAse) which catalyzes the second step of arginine degradation in eukayotic cell.
In one preferred embodiment, the reduced L-ornithine degradation activity is achieved by reducing the activity of
L-ornithine transaminase (OTAse) which catalyzes the second step of arginine degradation in S. cerevisiae. In
one preferred embodiment, the reduction of OTAse activity is achieved by deleting the OTAse encoding gene
CAR2 in S. cerevisiae. The gene deletion can be achieved by known methods in the art. The CAR2 deletion
improves the L-ornithine production.
In a preferred embodiment, the activity of arginase which catabolizes L-arginine to L-ornithine and urea is
increased in the eukaryotic cell. In a preferred embodiment, the activity of arginase which catabolizes L-arginine
to L-ornithine and urea is increased in the modified S. cerevisiae. The increasing activity of arginase could be
achieved by known methods in the art. For instance, the increasing activity of arginase could be achieved by
overexpressing the encoding gene of arginase. The arginase encoding gene can be from any known species, for
instance S. cerevisiae. In one preferred embodiment, the overexpressing of the CAR1 gene which encodes the
arginase is achieved in the modified S. cerevisiae. Surprisingly, the overexpression of CAR1 gene in the modified
yeast cell led to increased production of L-ornithine. Preferably, the yeast cell overexpresses a nucleotide
sequence encoding arginase comprising an amino acid sequence that has at least 40%, preferably at least 45,
50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 97, 98, 99% sequence identity with the amino sequence of SEQ ID NO: 1.
Preferably, the nucleotide sequence encodes arginase comprising the amino acid sequence of SEQ ID NO: 1.
In one preferred embodiment, the carbon channelling from a-ketoglutarate to L-ornithine is enhanced in the
modified eukaryotic cell. In one preferred embodiment, the carbon channelling from a-ketoglutarate to L-ornithine
is enhanced in the modified yeast cell. In a preferred embodiment, the carbon channelling from a-ketoglutarate
to L-ornithine is enhanced in the modified S.cerevisiae. Direct enhancing precursor supply pathway was a very
commonplace strategy in bacteria to boost more flux to the desired products, yet, the segmentation of precursor
intermediates in different subcellular organelles compromised the metabolic engineering endeavors in S.
cerevisiae. L-ornithine biosynthetic pathway is one of such complicated pathways which is subject to subcellular
compartmentalization: the downstream L-ornithine 'acetylated derivatives cycle' and the TCA cycle which gives
the precursors of L-glutamate are confined to the mitochondria, while the middle of L-glutamate supply pathway
is confined to cytoplasm. According to the metabolism architecture, three strategies were proposed to improve
the pathway efficiency between α-ketoglutarate node of TCA cycle and L-ornithine 'acetylated derivatives cycle'
as follows: (i) directly enhance the endogenous pathway in its quondam subcellular organelle and the subcellular
trafficking step; (ii) re-localize the L-glutamate synthesis reaction into mitochondria to avoid the subcellular
trafficking of L-glutamate and its precursor α-ketoglutarate and (iii) 'short-circuit' the total L-ornithine pathway
started from TCA cycle to cytosol to bypass the subcellular trafficking of L-glutamate and L-ornithine.
In one preferred embodiment, the carbon channelling from α-ketoglutarate to L-ornithine is enhanced in the
modified eukaryotic cell by directly enhancing the endogenous pathway in its quondam subcellular organelle and
the subcellular trafficking steps. In one preferred embodiment, the carbon channelling from α-ketoglutarate to L-
ornithine is enhanced in the modified S. cerevisiae by directly enhancing the endogenous pathway in its quondam
subcellular organelle and the subcellular trafficking steps. In one preferred embodiment, enhancing the
endogenous pathway in its quondam subcellular organelle and the subcellular trafficking steps is achieved by
overexpressing of any enzymes/proteins or any combinations of said enzymes/proteins in the pathway from a-
ketoglutarate to L-ornithine in the eukaryotic cell. In one preferred embodiment, enhancing the endogenous
pathway in its quondam subcellular organelle and the subcellular trafficking steps is achieved by increasing the
activity of any enzymes/proteins or any combinations of said enzymes/proteins in the pathway from a-
ketoglutarate to L-ornithine in S. cerevisiae. These enzymes/proteins comprise: acetylglutamate synthase
(glutamate N-acetyltransferase), acetylglutamate kinase and N-acetyl-gamma-glutamyl-phosphate reductase,
mitochondrial ornithine acetyltransferase, acetylornithine aminotransferase, NADP+-dependent glutamate
dehydrogenase, glutamine synthetase (GS), NAD+-dependent glutamate synthase (GOGAT), ornithine
transporter of the mitochondrial inner membrane, glutamate uniporter, mitochondrial inner membrane a-
ketoglutarate transporter. In one preferred embodiment, the increased activity of any of the said enzymes/proteins
or any combinations of thereof is achieved by overexpression the encoding genes. Preferably, at least one
endogenous or homologous pyruvate carboxylase is/are overexpressed in the eukaryotic cell according to the
invention. In one preferred embodiment, the increased activity of any of the said enzymes is achieved by
overexpressing the related genes in cytosol or mitochondria. Any genes either endogenous or heterogonous to
the modified eukaryotic cell could be chosen as the overexpressing targets. In one preferred embodiment, the
overexpression of any genes or any combinations of genes in the list comprising ARG2 (SEQ ID NO: 2), ARG5,
6 (SEQ ID NO: 3), ARG8 (SEQ ID NO: 4), ARG7 (SEQ ID NO: 5), GDH1 (SEQ ID NO: 6), GDH3 (SEQ ID NO: 7),
GLN1 (SEQ ID NO: 8), GLT1 (SEQ ID NO: 9), 0RT1 (SEQ ID NO: 10), GC (SEQ ID NO: 11) and 0DC1 (SEQ
ID NO: 12) which are all from S. cerevisiae is achieved.
In one preferred embodiment, L-ornithine 'acetylated derivatives cycle' is re-localized to cytosol in the
modified eukaryotic cell. In one preferred embodiment, L-ornithine 'acetylated derivatives cycle' is re-localized to
cytosol in the modified S. cerevisiae. In one preferred embodiment, L-ornithine 'acetylated derivatives cycle' is re-
localized to cytosol in the modified S. cerevisiae by increasing the enzyme activity of the related enzymes in the
said pathway from bacteria cell. In one preferred embodiment, L-ornithine 'acetylated derivatives cycle' is re-
localized to cytosol in the modified S. cerevisiae by overexpression all the genes in the said pathway from bacteria
cell. In one preferred embodiment, L-ornithine 'acetylated derivatives cycle' is re-localized to cytosol in the
modified S. cerevisiae by overexpression all the genes in the said pathway from bacteria cell, wherein the genes
comprising E. coli argAEc (SEQ ID NO: 23) and argBEc (SEQ ID NO: 24), and C. glutamicum argCcg (SEQ ID NO:
25), argDcg (SEQ ID NO: 26) and argJcg (SEQ ID NO: 27).
In certain preferred embodiment, the efficiency of carbon channeling from substrate to α-ketoglutarate is
enhanced in the modified eukaryotic cell. In certain preferred embodiment, the efficiency of carbon channeling
from substrate to α-ketoglutarate is enhanced in the modified yeast cell. In certain preferred embodiment, the
efficiency of carbon channeling from substrate to α-ketoglutarate is enhanced in the modified eukaryotic cell. In
certain preferred embodiment, the efficiency of carbon channeling from substrate to α-ketoglutarate is enhanced
in the modified S.cerevisiae.
In one preferred embodiment, the efficiency of carbon channeling from substrate to α-ketoglutarate is
enhanced by increase in the enzymes/proteins activity of at least one enzyme/protein in the pathway from carbon
substrate to the α-ketoglutarate in the modified eukaryotic cell. In one preferred embodiment, the efficiency of
carbon channeling from substrate to α-ketoglutarate is enhanced by increase in the enzymes/proteins activity of
at least one enzyme/protein in the pathway from carbon substrate to the α-ketoglutarate in the modified yeast cell.
In one preferred embodiment, the efficiency of carbon channeling from substrate to α-ketoglutarate is enhanced
by increase in the enzymes/proteins activity of at least one enzyme/protein in the pathway from carbon substrate
to the α-ketoglutarate in the modified S. cerevisiae cell. In one preferred embodiment, the efficiency of carbon
channeling from substrate to α-ketoglutarate is enhanced by increasing the enzyme/protein activity of at least one
enzyme/protein in the pathway from carbon substrate to the α-ketoglutarate in the modified S. cerevisiae cell,
wherein the increasing of the activity of enzymes/proteins is achieved by overexpressing the encoding genes of
said enzymes/proteins. Preferably, the eukaryotic cell according to the present disclose, overexpress a nucleotide
sequence encoding a pyruvate carboxylase (PYC), preferably a pyruvate carboxylase that is active either at
cytosol or mitochondria upon expression of a nucleotide sequence encoding a PYC, for instance a PYC
comprising an amino acid sequence according to SEQ ID NO: 13. Preferably, an endogenous or homologous
pyruvate carboxylase is overexpressed in the eukaryotic cell according to the invention. It was found that
overexpressing an endogenous pyruvate carboxylase (PYC) resulted in increased L-ornithine production levels
by the eukaryotic cell according to the present disclosure.
Preferably, the eukaryotic cell according to the present disclose, overexpresss a nucleotide sequence
encoding a citrate synthase (CS) which catalyzes the condensation of acetyl coenzyme A and oxaloacetate to
form citrate, preferably a citrate synthase that is active either at cytosol or mitochondria upon expression of a
nucleotide sequence encoding a CS, for instance a CS comprising an amino acid sequence according to SEQ ID
NO: 14. Preferably, an endogenous or homologous pyruvate carboxylase is overexpressed in the eukaryotic cell
according to the invention. Surprisingly, it was found that overexpressing an endogenous citrate synthase (CS)
resulted in increased L-ornithine production levels by the eukaryotic cell according to the present disclosure.
Preferably, the eukaryotic cell according to the present disclose, the activity of pyruvate dehydrogenase (PDH)
is increased. Preferably, the increase activity of PDH is achieved by overexpressing at least one subunit of PDH.
Preferably, the nucleotide sequence encoding E 1 alpha subunit of the pyruvate dehydrogenase (PDH) complex,
preferably E 1 alpha subunit of the pyruvate dehydrogenase (PDH) that is active either at cytosol or mitochondria
is upon expression of a nucleotide sequence encoding said protein, for instance a E 1 alpha subunit of the pyruvate
dehydrogenase (PDH) comprising an amino acid sequence according to SEQ ID NO: 15. Preferably, an
endogenous or homologous pyruvate carboxylase is overexpressed in the eukaryotic cell according to the
invention. Surprisingly, it was found that overexpressing an endogenous pyruvate dehydrogenase (PDH) subunit
resulted in increased L-ornithine production levels by the eukaryotic cell according to the present disclosure.
Preferably, the eukaryotic cell according to the present disclose, overexpresses a nucleotide sequence
encoding a aconitase, preferably an aconitase is active either at cytosol or mitochondria upon expression of a
nucleotide sequence encoding a aconitase, for instance an aconitase comprising an amino acid sequence
according to SEQ ID NO: 16. Preferably, an endogenous or homologous aconitase is overexpressed in the
eukaryotic cell according to the invention. Surprisingly, it was found that overexpressing an aconitase resulted in
increased L-ornithine production levels by the eukaryotic cell according to the present disclosure.
Preferably, the eukaryotic cell according to the present disclose, overexpresses a nucleotide sequence
encoding an isocitrate dehydrogenase (IDP) which catalyzes the oxidation of isocitrate to a-ketoglutarate,
preferably an IDP is active either at cytosol or mitochondria upon expression of a nucleotide sequence encoding
an IDP, for instance an IDP comprising an amino acid sequence according to SEQ ID NO: 17. Preferably, an
endogenous or homologous IDP is overexpressed in the eukaryotic cell according to the invention. It was found
that overexpressing an IDP resulted in increased L-ornithine production levels by the eukaryotic cell according to
the present disclosure.
In one preferred embodiment, the activity of protein which uptake pyruvate form cytosol to mitochondria is
increased in the eukaryotic cell according to the present disclosure. In one preferred embodiment, at least one
subunit of the mitochondrial pyruvate carrier from S. cerevisiae is subject to overexpression. In one preferred
embodiment, MPC1 (SEQ ID NO: 18) orMPC2 (SEQ ID NO: 19) orMPC3 (SEQ ID NO: 20) or any combinations
of MPC1, MPC2, MPC3 is subject to overexpression. Surprisingly, it was found that overexpressing pyruvate
carrier proteins resulted in increased L-ornithine production levels by the eukaryotic cell according to the present
disclosure.
In one preferred embodiment, at least one enzyme/protein or any combinations of thereof is/are increased,
the enzymes/proteins are as follows: isocitrate dehydrogenase, mitochondrial pyruvate carrier, pyruvate
carboxylase, citrate synthase (CS), pyruvate dehydrogenase (PDH).
In one preferred embodiment, the carbon substrate uptake activity is decreased in the eukaryotic cell
according to the present disclose. Many technologies/strategies known in the art can be used to decrease the
activity of carbon substrate uptake. In one preferred embodiment, the carbon substrate uptake activity is
decreased in the eukaryotic cell according to the present disclose, wherein the decrease activity of carbon uptake
is achieved by decreasing the activity of the transport proteins which transport the carbon substrate from
extracellular environment to the cytosol. Preferably, the decreasing of transport proteins which transport the
carbon uptake is achieved by increase in the activity of special proteins which regulate the carbon uptake. In one
preferred embodiment, stability of one of the proteins in the glucose regulation systems is achieved by
overexpression the mutated MTH1 (SEQ ID NO: 22), encoding the internal deleted version of glucose transporter
regulation protein. Surprisingly, more carbon flux from carbon substrate was boosted into L-ornithine and less or
no ethanol production was seen with the modified S. cerevisiae.
In one preferred embodiment, the activity of the NADH alternative oxidase is increased to increase the
efficiency of carbon chanelling from carbon substrate to a-ketoglutarate in the modified eukaryotic cell. In one
preferred embodiment, the activity of the NADH alternative oxidase is increased to increase the efficiency of
carbon chanelling from the carbon substrate to a-ketoglutarate in the modified yeast cell. In one preferred
embodiment, the activity of the NADH alternative oxidase (AOX) is increased to increase the efficiency of carbon
channeling from carbon substrate to α-ketoglutarate in the modified S. cerevisiae. In one preferred embodiment,
the activity of the NADH alternative oxidase is increased to increase the efficiency of carbon chanelling from
carbon substrate to α-ketoglutarate in the modified S. cerevisiae, wherein the increased activity of AOX is
achieved by overexpression of AOX from Hansenula anomala {HaAOX) (SEQ ID NO: 28). Surprisingly, more
carbon flux from carbon substrate was boosted into L-ornithine and less or no ethanol production was seen with
the modified S. cerevisiae.
In one preferred embodiment, the eukaryotic cell according to the present invention may be able to grow on
any suitable carbon source known in the art and convert it to L-ornithine. The eukaryotic cell may be able to
convert directly plant biomass, hemicelluloses, celluloses, pectines, rhamnose, fucose, maltose, galactose,
maltodextrines, ribose, ribulose, or starch, starch derivatives, sucrose, glycerol and lactose. Hence, a preferred
host organism expresses enzymes such as hemicellulases (e.g. endo- and exo-xylanases, arabinases) and
cellulases (endocellulases and exocellulases) necessary for the conversion of cellulose into glucose monomers
and hemicellulose into arabinose and xylose monomers, pectinases able to convert pectines into galacturonic
acid and glucuronic acid or amylases to convert starch into glucose monomers. In one preferred embodiment, the
modified eukaryotic cell is able to convert a carbon source selected from the group consisting of glucose, xylose,
arabinose, fructose, galactose, sucrose, glycerol raffinose and lactose. In another aspect, the present invention
relates to a process for the preparation of L-ornithine, comprising fermenting or cultivating the eukaryotic cell
according to the present invention, wherein L-ornithine is prepared.
In one preferred embodiment, the L-ornithine produced by the modified eukaryotic cell described herein can
be incorporated into one or more food, and/or chemical products.
In one preferred embodiment, the genetically modified eukaryotic cells according to the present disclose
described herein can be incorporated into food and/or drink production. In one preferred embodiment, the
genetically modified eukaryotic cells according to the present disclose described herein can be incorporated into
beer brewing, wherein the beer comprises moderate L-ornithine. In one preferred embodiment, the genetically
modified eukaryotic cells according to the present disclose described herein can be incorporated into bread baking,
wherein the baking products comprise moderate L-ornithine.
In one preferred embodiment, the genetically modified eukaryotic cells according to the present disclose can
be further modified to produce chemical compound which can be produced in the cell using L-ornithine as the
precursor.
In certain embodiments, the present disclosure relates to a modified cell, such as yeast or bacterial cell,
wherein the cell can overproduce polyamines, such as putrescine, spermidine or spermine. Said overproduction
is obtained by combining some or all of the modifications for ornithine production mentioned above with
overexpression of the enzymatic steps responsible for production of these compounds, down-regulation of
competing and/or inhibitory reactions, overexpression of various export proteins, down-regulation of various
uptake proteins and modification of expression of various proteins associated with polyamine toxicity, giving a
very effective total process.
In a preferred embodiment, the activity of ornithine decarboxylase (ODC) which catalyzes the conversion of
ornithine to putrescine is increased to increase flux towards putrescine in yeast. The increase in activity of ODC
could be achieved by known methods in the art. For instance, the increased activity of ODC could be achieved
by overexpressing the encoding gene of ODC. The ODC encoding gene can be from any known species, for
instance S. cerevisiae. In one preferred embodiment the overexpression of the native SPE1 gene which encodes
the ODC is achieved in the modified S. cerevisiae. In addition, heterologous ODC from other eukaryotic or
prokaryotic sources can be expressed (e.g. from Escherichia coli, Triticum aestivum, Oryza sativa, Glycine max,
Citrus sinesis, Homo sapiens). Furthermore, a mutated, highly-active ODC from E. coli containing modifications
in the 1163 and E165 residues can be expressed in yeast (Choi et al., 2015). To further increase the activity of
ODC in yeast, the activity of the ODC antizyme, which binds to ODC, inactivates it, and targets it for degradation,
could be decreased by deletion or promoter exchange. These modifications can be combined with the
modifications for ornithine over-production described above. It has also been previously shown that deletion of
Methylthioadenosine phosphorylase (encoded by MEU1) in yeast results in an increase in ODC activity and large
elevation in polyamine pools (Subhi et al., 2003). Therefore, deletion or down-regulation of this gene can be
combined with the above modifications. Furthermore, down-regulation of spermdine synthase (SPDS), which
catalyzes conversion of putrescine to spermdine, can also be combined with the modifications above to increase
flux towards putrescine.
In another embodiment, flux towards spermidine is increased in yeast by increasing the activities of S-
adenosylmethionine decarboxylase (SAMDC) and spermidine synthase (SPDS), which catalyze conversion of
putrescine into spermidine. This can be achieved by, for example, overexpression of the native SPE2 and SPE3
genes which encode SAMDC and SPDS in the modified S. cerevisiae. In addition, heterologous SAMDC and
SPDS from other eukaryotic or prokaryotic sources can be expressed (e.g. from Escherichia coli, Triticum
aestivum, Oryza sativa, Glycine max, Citms sinesis, Homo sapiens). To further increase flux towards spermidine
production, the SPE4 gene, which encodes spermine synthase (SPS), can be down-regulated. Flux towards
spermidine can also be increased by overexpressing yeast polyamine oxidase {FMS1), which catalyzes
conversion of spermine to spermidine, or spermine oxidase (SMOX; EC 1.5.3.16) from other sources (e.g.
mammalian) for the same reaction. These modifications can be combined with the modifications for ornithine
and/or putrescine over-production described above.
In another embodiment, flux towards spermine production is increased by increasing the activity of spermine
synthase (SPS), which catalyzes the conversion of spermidine to spermine. This can be achieved by, for example,
overexpression of the native SPE4 gene, which encodes SPS in the modified S. cerevisiae. In addition,
heterologous SPS from other eukaryotic or prokaryotic sources can be expressed (e.g. from Triticum aestivum,
Oryza sativa, Glycine max, Citms sinesis, Homo sapiens). These modifications can also be combined with
increase in the activities of ODC, SAMDC and/or SPDS, as well as down-regulation of the ODC antizyme. In
addition, to reduce conversion of spermine to spermidine, yeast FMS1 can also be down-regulated.
In another embodiment, flux towards polyamines can be increased by down-regulation of competing
reactions. For example, polyamine acetyltransferase (encoded by PAA1 in yeast) can acetylate various
polyamines such as putrescine, spermidine and spermine. To reduce this, this enzyme can be down-regulated or
deleted.
In another embodiment, export of polyamines to the media can be facilitated. This can be accomplished by
overexpression of different export proteins, such as yeast TP01, TP02, TP03, TP04 and TP05; Escherichia coli
MdtJI, mammalian SLC3A2, Bacillus subtillis Bit transporter and/or mammalian MDR1. In addition, genes
associated with polyamine uptake, such as yeast DUR3, SAM3, AGP2 and/or GAP1 can be down-regulated or
deleted. Alternatively, increased intracellular presence of polyamines could be achieved by down-regulation or
deletion of the polyamine transporters TP01, TP02, TP03, TP04 or TP05.
In another embodiment, the resistance of the above strains to polyamine toxicity is increased. Down-
regulation and/or deletion of several genes have been associated with increased resistance to polyamine toxicity
in yeast. This includes SR protein kinase (SRPK) (encoded by SKY1), Putative serine/threonine protein kinase
(encoded by PTK2), BRP1 and FES1. In addition, overexpression of several native genes has been associated
with increased resistance to polyamine toxicity. This includes QDR3 and YAP1. The above genes can be over-
expressed and/or down-regulated in various combinations to allow for optimal resistance to polyamine toxicity in
yeast.
In certain embodiments, the present disclosure relates to a modified eukaryotic cell capable of over¬
producing agmatine. Said production can be accomplished either independently, or by combining some of the
modifications described for ornithine production above with the overexpression of some of the enzymatic steps
responsible for agmatine production and down-regulation of competing reactions.
In one embodiment, flux can be directed from ornithine to arginine and/or agmatine production by increasing
the activities of ornithine carbamoyltransferase [EC:2.1.3.3], argininosuccinate synthase (EC:6.3.4.5) and
argininosuccinate lyase [EC:4.3.2.1]. This can be done, for example, by overexpressing the native yeast ARG3,
ARG1, ARG10 and/or ARG4 genes. In addition, heterologous genes encoding these activities can also be
expressed. To decrease competing reactions, the native arginase [CAR1) genes can be deleted or down-
regulated. Furthermore, conversion of arginine to agmatine can be accomplished by introduction of a
heterologous gene encoding arginine decarboxylase [EC:4.1.1.19] (e.g. E. coli SpeA or Adi, Desulfovibrio
magneticus pdaA, Homo sapiens AZIN2, etc. ) .
In certain embodiments, putrescine can be produced from agmatine by introduction of genes encoding for
enzyme activities of agmatinase (e.g E. coli SpeB), which converts agmatine to putrescine and urea (e.g E. coli
SpeB). In addition, agmatine could also be converted to putrescine by introduction of two heterologous steps:
hydrolytic deamination of agmatine to N-carbamoylputrescine by agmatine deiminase (e.g. AguA from
Pseudonomas aeroginosa) and hydrolysis of the carbomoyl group to yield putrescine in a reaction catayzed by
N-carbamoylputrescine amidohydrolyase (e.g. AguB from Pseudonomas aeroginosa; PTC from Enterococcus
faecalis).
In certain embodiments, spermidine can be produced from agmatine. In some extremophiles, agmatine
aminopropyltransferase uses S-adenosylmethionine (dsSAM) as a donor to produce aminopropylagmatine which
is subsequently hydrolysed to spermidine and urea by aminopropylagmatine ureohydrolase. Genes encoding
enzymes for these activities can also be expressed in yeast to facilitate spermidine production (e.g. Thermococcus
kodakarensis TK0147, TK0240, TK0474 and TK0882, Thermus thermophiles speE and speB).
In a another embodiment, spermidine can be produced via the condensation of L-aspartate semialdehyde
and putrescine via carboxy(nor)spermidine dehydrogenase (CANSDH) yielding carboxyspermidine, followed by
decarboxylation by carbox(nor)spermidine decarboxylase (CANSDC). Genes encoding enzyme with these
activities can be expressed to facilitate spermidine production (e.g. CANSDH and CANSDC from Campylobacter
jejuni, Vibrio cholera, Vibrio cholerae or Vibrio a/g/no/yf/civs).AIternatively, aminopropyl transferase activity which
uses dcSAM to synthesize norspermidine from 1,3-diaminopropane from Clostridium thermohydrosuluricum can
also be expressed.
In certain embodiments, additional reactions that could potentially compete with polyamine synthesis could
be deleted or down-regulated in yeast. This can include reactions involved in pathways that lead to GABA (γ-
aminobutyric acid), such as those encoded by UGA1, UGA2, UGA3 and/or UGA4).
In certain embodiments, production of polyamines from bacterial sources can be achieved. For production
of L-ornithine and putrescine, organisms like Escherichia coli and Corynebacterium glutanicum are feasible hosts
for production. This makes them good platform strains for the production for spermidine and spermine through
overexpression of intrinsic or heterologous spermidine synthase and S-adenosylmethionine decarboxylase.
Modifications in E. coli WL3110 (orig. K12 W3110 (CGSC, Coli Genetic Stock Center) to increase ornithine and
putrescine production respectively can be implemented as described by Quian et al. (2009). For example, such
modifications can comprise enhancing the precursor supply (e.g., deletion of argl gene), inactivating putrescine
degradation and utilization pathways (e.g., deletion of speG; puuPA, argR) and deleting rpoS, a stress responsive
polymerase sigma factor. In addition to, or combined with the former changes, genes coding for ornithine
decarboxylase converting ornithine to putrescine and ornithine biosynthetic genes [argC-E] can be overexpressed
either through the use of plasmids or chromosomal integration. This former platform strain can additionally be
transformed with either plasmids for overexpression of endogenous or heterologous speE (E.C.: 2.5.1.16; SEQ
ID NO: 37) and speD (EC 4.1.1.50; SEQ ID NO: 39) genes. Spermidine exporters derived from, for example, E.
coli, including the mdtJl complex genes (SEQ ID NOs: 40-41) or Bit from, for example, B. subtilis (SEQ ID NO:
42) represent possible candidates for over/co-expression with the "platform" stain described herein to increase
the production of spermidine/spermine. In other embodiments, in order to increase the production of spermine,
heterologous spermine synthases (E.C. 2.5.1.22) from, for example, eukaryotic sources , including S. cerevisiae,
Triticum aestivum, Oryza sativa, Glycine max, Citrus sinesis, Homo sapiens can be expressed.
In yet other embodiments, polyamines can be produced in C. glutamicum. Modifications to increase ornithine
production in C. glutamicum strain ATCC 13032 can be achieved through, for example, deletion of proB and argF,
which block competing pathways, deletion of argR gene, which is the repressor of the L-arginine operon,
overexpression of argCJBD from C. glutanicum (ATCC 2 1831 start codon change of pgi and zwf ) , which lead to
enrichment of the NADPH pool, and/or replacing native promoter of operon with a strong sod promoter. In
some embodiments, in order to increase putrescine production the platform strain can be engineered to
overexpress the ornithine decarboxylase gene, speC (EC 4.1 . 1 . 1 9; SEQ ID NO: 44) from E. coli and/or by deletion
of the carbamoyl-transferase argF gene.
In some embodiments, in order to increase spermidine production in the platform strain, the endogenous
spermidine synthase gene speE (SEQ ID NO: 45) and E. coli S-adenosylmethionine decarboxylase speD (EC
4.1.1.50; SEQ ID NO: 39) can be overexpressed. The former strains can additionally be engineered to increase
the export, as described elsewhere herein. In other embodiments in order to increase spermidine, heterologous
spermine synthases (E.C. 2.5.1.22) from eukaryotic sources can be overexpressed. For example, the former
spermine synthases can be derived from, for example, S. cerevisiae [Spe4, G : 3201942: SEQ D NO: 43),
Triticum aestivum, Oryza sativa, Glycine max, Citrus sinesis and/or Homo sapiens.
The following examples are included to demonstrate preferred embodiments of the disclosure. It should be
appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent
techniques discovered by the inventor to function well in the practice of the disclosure, and thus can be considered
to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present
disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still
obtain a like or similar result without departing from the spirit and scope of the disclosure.
In general, any modification may be applied to a cell to impart or increase accumulation and/or production of
L-ornithine or a chemical compound which can be produced in the cell using L-ornithine. In many cases, the
modification comprises a genetic modification, wherein the genetic modifications may be introduced into cells by
any available means including transfer (e.g., via transformation or mating) of nucleic acids and/or chemical
mutation.
An aspect of the embodiments relates to a eukaryotic cell capable of producing L-ornithine. The eukaryotic
cell is genetically modified for attenuated activity of an ornithine carbamyoltransferase.
In an embodiment, the eukaryotic cell is genetically modified for attenuated expression of a gene encoding
the ornithine carbamyoltransferase in the eukaryotic cell.
In an embodiment, the eukaryotic cell has a native promoter of the gene encoding the ornithine
carbamyoltransferase replaced by a weak constitutive promoter. In a particular embodiment, the eukaryotic cell
has a native promoter of the gene ARG3 replaced by a promoter of the gene KEX2.
In an embodiment, the eukaryotic cell is genetically modified by deletion or disruption of a gene encoding an
L-ornithine transaminase. In a particular embodiment, the eukaryotic cell is genetically modified by deletion or
disruption of the gene CAR2.
The above disclosed embodiments relates to a eukaryotic cell, such as fungal cell and preferably a yeast
cell, genetically modified according to module 1 (M 1) as described herein.
In an embodiment, the eukaryotic cell is genetically modified for enhanced L-ornithine biosynthesis from
-
ketoglutarate.
In an embodiment, the eukaryotic cell is genetically modified for cytosolic L-ornithine biosynthesis from
-
ketoglutarate.
In an embodiment, the eukaryotic cell comprises at least one of gene selected from a group consisting of a
gene encoding a cytosolic glutamate N-acetyltransferase, a gene encoding a cytosolic N-acetylglutamate kinase,
a gene encoding a cytosolic aeety gamma gi tamyi pbosphate reductase, a gene encoding a cytosolic
acetySornithine aminotransferase and a gene encoding a cytosolic ornithine acety!transferase. in a particular
embodiment, the eukaryotic ce l comprises the genes a A and arg B fro Escherichia c i and the genes
argCcg,, argDcg and rgJ gfrom Corynebaderium giuta ni u .
in an embodiment the yeast is genetically modified for overexpression of at least one gene selected from a
group consisting of a gene encoding an N-acety!-gamma-glutamyi-phosphate reductase, a gene encoding a
mitochondria! ornithine acety!transferase. a gene encoding an acetylornithine aminotransferase and a gene
encoding an acety!g!umate synthase. In a particular embodiment, the yeast is genetically modified for
overexpression of the genes ARG5, RG7, ARG8 and ARG2,
in an embodiment, the eukaryotic cell is genetically modified for overexpression of at least one gene selected
from a group consisting of a gene encoding a L-ornithine transporter, a gene encoding a L-glutamate transporter
and a gene encoding NADP-^dependent glutamate dehydrogenase. In a particular embodiment, the eukaryotic
cell is genetically modified for overexpression of the genes 0RT1, AGC1, GDH1.
The above disclosed embodiments relates to a eukaryotic cell, such as fungal cell and preferably a yeast
cell, genetically modified according to module 2 (M2) as described herein. As mentioned above, the genetical
modification according to module 2 is preferably applied to a eukaryotic cell that also is genetically modified
according to module 1. However, the embodiments are not limited. Thus, an aspect of the embodiments relates
to a yeast cell genetically modified according to module 2 but not necessarily according to module 1. This aspect
of the embodiments thereby relates to a eukaryotic cell capable of producing L-ornithine. The eukaryotic cell is
genetically modified for enhanced L-ornithine biosynthesis from a-ketoglutarate. The above described optional
but preferred embodiments relating to the genetical modification according to module 2 also applies to the aspect
of a eukaryotic cell genetically modified according to module 2 but not necessarily according to module 1.
In an embodiment, the eukaryotic cell is genetically modified for enhanced a-ketoglutarate biosynthesis.
In an embodiment, the eukaryotic cell is genetically modified for attenuated glucose uptake.
In an embodiment, the eukaryotic cell is genetically modified for overexpression of a gene encoding a glucose
transporter regulator protein. In a particular embodiment, the eukaryotic cell is genetically modified for
overexpression of the gene MTH1 or the gene ΜΤΗ1-∆ Τ, wherein the gene ΜΤΗ1-∆ Τ is an internal deletion
version of the gene MTH1.
The above disclosed embodiments relates to a eukaryotic cell, such as fungal cell and preferably a yeast
cell, genetically modified according to module 3 (M3) as described herein. As mentioned above, the genetical
modification according to module 3 is preferably applied to a eukaryotic cell that also is genetically modified
according to module 1 and module 2 . However, the embodiments are not limited. Thus, an aspect of the
embodiments relates to a yeast cell genetically modified according to module 3 but not necessarily according to
module 1 or module 2 . This aspect of the embodiments thereby relates to a eukaryotic cell capable of producing
L-ornithine. The eukaryotic cell is genetically modified for enhanced α -ketoglutarate biosynthesis. The above
described optional but preferred embodiments relating to the genetic modification according to module 3 also
applies to the aspect of an eukaryotic cell genetically modified according to module 3 but not necessarily according
to module 1 or module 2 .
Thus, the embodiments encompass a eukaroytoic cell genetically modified according to module 1, a
eukaryotic cell genetically modified according to module 2, a eukaryotic cell genetically modified according to
module 3, a eukaryotic cell genetically modified according to module 1 and module 2, a eukaryotic cell genetically
modified according to module 1 and module 3, a eukaryotic cell genetically modified according to module 2 and
module 3 and a eukaryotic cell genetically modified according to module 1, module 2 and module 3 .
In an embodiment, the eukaryotic cell is genetically modified for overexpression of a gene encoding an
arginase. In a particular embodiment, the eukaryotic cell is genetically modified for overexpression of the gene
CARL
The above described embodiments and particular embodiments can be combined in any suitable manner.
Hence, the present invention also encompasses various combinations of different genetical modifications of the
above described embodiments to form a eukaryotic cell capable of producing L-ornithine.
In an embodiment, the eukaryotic cell is genetically modified by:
having a native promoter of the gene ARG3 replaced by a promoter of the gene KEX2;
deletion or disruption of the gene CAR2;
overexpression of the genes 0RT1, AGC1, GDH1;
expression of the genes argAtx and argBtx from Escherichia coii and the genes argCc g > argDcg and argJcg
from C n bacterium gl ta ni u and
overexpression of the gene ΜΤΗ1-∆ Τ.
In an embodiment, the eukaryotic cell is also genetically modified for overexpression of the gene CARL
Further aspects of the embodiments relates to a eukaryotic cell capable of producing a polyamine using L-
ornithine as a starting material or intermediate product in the production of the polyamine. In a preferred
embodiment, the polyamine is selected from a group consisting of putrescine, spermidine and spermine.
Thus, in embodiment the eukaryotic cell is capable of producing a polyamine selected from the group
consisting of putrescine, spermidine and spermine. The eukaryotic cell is also genetically modified for
overexpression of a gene encoding ornithine decarboxylase (ODC) and/or attenuated activity of ODC antienzyme.
In a particular embodiment, the eukaryotic cell is genetically modified for overexpression of the gene SPE1
and deletion or disruption of the gene OAZL
In an embodiment, the eukaryotic cell is capable of producing a polyamine selected from the group consisting
of spermidine and spermine. The eukaryotic cell is also genetically modified for overexpression of a gene
encoding an S-adenosylmethionine decarboxylase and/or a gene encoding a spermidine synthase.
In a particular embodiment, the eukaryotic cell is genetically modified for overexpression of the genes SPE2
and SPE3.
In an embodiment, the eukaryotic cell is capable of producing a polyamine selected from the group consisting
of spermidine and spermine. The eukaryotic cell is also genetically modified for expression of a gene encoding a
carboxynorspermidine dehydrogenase and/or a gene encoding a carboxynorspermidine decarboxylase.
In a particular embodiment, the eukaryotic cell is genetically modified for expression of:
i) the genes Cj0172c and Cj1515c from Capylobacter jejuni; or
ii) the genes VC1624 and VC1623 from Vibrio cholera; or
iii) the genes Lys1 and nspC from Bacteriodes uniformis.
In an embodiment, the eukaryotic cell is capable of producing spermine. The eukaryotic cell is also
genetically modified for overexpression of a gene encoding a spermine synthase.
In a particular embodiment, the eukaryotic cell is genetically modified for overexpression of the gene SPE4.
In an embodiment relating to the eukaryotic cell capable of producing a polyamine, the eukaryotic cell is
genetically modified for overexpression of a gene encoding a polyamine transporter. In a particular embodiment,
the eukaryotic cell is genetically modified for overexpression of at least one gene selected from the group
consisting of TP01, TP02, TP03, TP04 and TP05.
In an embodiment, the eukaryotic cell capable of producing L-ornithine and optionally the polyamine is a
fungal cell, preferably a yeast cell.
In an embodiment, the yeast cell is selected from a genus consisting of the group consisting of
Saccharomyces, Cryptococcus, Trichosporon, Zygosaccharomyces, Debaromyces, Pichia,
Schizosaccharomyces, Trigonopsis, Brettanomyces, Aureobasidium, Nadsonia, Lipomyces, Torulopsis,
Kloeckera, Phaffia, Rhodotorula, Candida, Hansenula, Kluyveromyces, Yarrowia, and Schwanniomyces. In a
particular embodiment, the yeast cell is selected from a genus consisting of the group consisting of
Saccharomyces, Yarrowia, Zygosaccharomyces, Kluyveromyces and Pichia spp. In an embodiment, the yeast
cell is preferably selected from the group consisting of Saccharomyces cerevisiae, Saccharomyces boulardii,
Zygosaccharomyces bailii, Kluyveromyces lactis, Yarrowia lipolytica, Schizosaccharomyces pombe, Hansenula
anomala, Candida sphaerica, and Schizosaccharomyces malidevorans, such as Saccharomyces cerevisiae.
A further aspect of the embodiments relates to a process for production of L-ornithine. The process
comprising cultivating a eukaryotic cell according to any of the embodiments disclosed herein and in particular
mentioned in the foregoing in the presence of a carbon source.
Yet another aspect of the embodiments relates to a process for production of a polyamine selected from the
group consisting of putrescine, spermidine and spermine. The process comprising cultivating a eukaryotic cell
according to the embodiments above relating to a eukaryotic cell capable of producing a polyamine in the
presence of a carbon source.
In an embodiment, the carbon source is selected from a group consisting of hemicelluloses, celluloses,
pectines, rhamnose, fucose, maltose, galactose, maltodextrines, ribose, ribulose, starch, sucrose, glycerol,
lactose, glucose, xylose, arabinose, fructose, galactose and glycerol raffinose and lactose.
EXAMPLES
All engineered yeast strains were constructed (Table 1 -3) from S. cerevisiae strain CEN.PK 113-1 1C
(MATa SUC2 MAL2-8c his3A1 ura3-52).
Example 1
Strain construction of ornithine-overproducing strains
All the plasmids used in this study can be found in Table 4 . Plasmids (G01, G02, G03, G04, Y01, Y02,
Y03 Y04 and Y03) were constructed according to MOPE strategy and DNA assembler (Shao et al., 2009). The
gene expressing modules consisted of a promoter, a structural gene, a terminator, and the promoter of the next
module for homologous recombination. The promoter TEF1p, TDH3p, PGK1p and HXT7p, terminator
FBA1t, CYC1t ,TDH2t and ADH2t, were PCR-amplified from the genomic DNA of S. cerevisiae CEN.PK.113-5D.
The TPIp and the terminator pYX212t were PCR-amplified from plasmid pYX21 2 . Genes ARG2, ARG5, 6, ARG7,
ARG8, CIT1, AC02, IDP1, PYC2, GLT1 and GLN1 were amplified from the genomic DNA of S. cerevisiae
CEN.PK.113-5D. PDA1 and mutated mPDA1 were PCR-amplified from plasmid pRS416-PDA1 and pRS416-
PDA1 [S313A] respectively (Oliviera et al., 2012). HoAOXI, argJcg, argCcg, argDcg, and argBcg were codon-
optimized and purchased from GenScript. argAEc and argBEc were PCR-amplified from the genomic DNA of E.
coil The mutated MTH1-AT was PCR-amplified from the genomic DNA of S. cerevisiae TAM (Oud et al., 201 2).
argBcg, and argJcg were targeted to the mitochondria using the N-terminal mitochondrial localization signal from
subunit IV of the yeast cytochrome c oxidase (CoxlV) (Avalos et al., 2013). All modules were constructed with the
one-step PCR strategy similar to overlap extension PCR. The expression modules were co-transformed by
electroporation with linearized vector pYX212 or p423GPD into S. cerevisiae CEN.PK 3-11 C, and the
recombinants appeared on the corresponding plates after 2-4 days. Selected colonies formed on the plates were
cultured in 5 mL of YPD liquid medium at 30 °C for 72 h . Recovered plasmids were checked by PCR to verify the
assembled pathways. Alternatively, positive plasmids were also transformed into E. coli DH5a, recovered,
digested by the relative restriction endonuclease, and analyzed by gel electrophoresis. Other plasmids used in
this study were constructed according to the regular cloning strategy.
To replace the ARG3 promoter, the HXT1 promoter and KEX2 promoter were amplified from genomic DNA
by PCR. The DNA cassette including the new promoter, the kanMX cassette and both 5' and 3' parts of the ARG3
promoter was constructed following the strategy of MOPE. Following the transformation of these cassettes into
S. cerevisiae, the correct transformants were selected and verified by colony PCR. Following a similar strategy,
0RT1, 0DC1, AGC1, GDH1, GDH2, GDH3, HaAOXI and Γ ί -∆ were integrated into the chromosome of S.
cerevisiae background strains, yielding strains with modification in the URA3, YPRCT 3 or KGD2 sites of
chromosome (Flagfeldt et al., 2009). Similar to argBcg and argJcg, GDH1 and GDH2 were targeted to the
mitochondria using the N-terminal mitochondrial localization signal from subunit IV of the yeast cytochrome c
oxidase (CoxlV). Variation combinations of plasmids and background strains yielded L-ornithine producing strains.
Yeast strains without plasmids were maintained on YPD plates containing 10 g yeast extract, 20 g casein
peptone, 20 g glucose and 20 g agar. Plasmid carrying yeast strains were selected on synthetic dextrose
(SD) agar containing 6.9 g yeast nitrogen base w/o amino acids (Formedium, Hunstanton, UK), 20 g glucose,
and 20 g agar. Strains containing the kanMX cassette were selected on YPD plates containing 200 mg G418
(Formedium, Hunstanton, UK). Defined minimal medium (Delft medium) as described before was used for both
batch cultivations and fed-batch fermentations of L-ornithine producing strains (Scalcinati et al., 2012). Luria
Bertani (LB) broth with 80 mg 1-1 ampicillin was used for maintenance of E. coli DH5a harboring appropriate
plasmids. L-ornithine was quantified using a ninhydrin colorimetric assay as described previously (Chinard, 1952).
Example 2
L-arginine leaky auxotroph enables L-ornithine overproduction
As an intermediate of L-arginine biosynthesis in S. cerevisiae, L-ornithine can be converted to L-citrulline
catalyzed by ornithine carbamoyltransferase {ARG3) in cytoplasm after export from the mitochondria, and L-
ornithine biosynthesis rate is limited by the presence of L-arginine due to the feedback inhibition and repression
of the key enzymes. However, deletion of ARG3 results in a L-arginine auxotrophy and a need of L-arginine
supplementation, which adds additional costs and might take problems in large-scale process control. Thus, as
part of this invention, we tested whether fine-tuning the ARG3 expression rather than full blocking would be a
better strategy, as L-arginine can still be synthesized at controllable lower level to support the growth and also
can limit the negative regulation of L-arginine on L-ornithine biosynthesis. Since promoter replacement can be a
feasible stratgey, we first weakened the ARG3 expression by replacing its native promoter with the promoter of
HXT1 (Low-affinity glucose transporter of the major facilitator superfamily) and KEX2 (Ca2+ dependent serine
protease involved in protein processing)(Scalcinati et al. 201 2) (Fig. 1a). To replace the ARG3 promoter, the HXT1
promoter and KEX2 promoter were amplified from genomic DNA of S. cerevisiae strain CEN.PK113-5D by PCR.
The DNA cassette including the new promoter, the kanMX cassette and both 5' and 3' parts of the ARG3 promoter
was constructed following the strategy of MOPE as described in Example 1 above. Following the transformation
of these cassettes into S. cerevisiae, the correct transformants were selected and verified by colony PCR. This
resulted in strains M1a (HXT1) and M1b (KEX2).
This strategy resulted in increased production of ornithine (Fig. 1b), with both strains in which the ARG3
promoter was replaced with a weaker promoter displaying improved overall production. The choice of promoter
was also highly relevant to ornithine production, wherein the strain with the weakest promoter {KEX2) had a 75%
higher titer (42 mg/L) compared to the strain with the HXT1 promoter (24 mg/U as shown in Figure 1b.
Example 3
Pathway re-localization and subcellular trafficking engineering elevates L-ornithine synthesis
After the optimization of L-ornithine consumption, we optimized the L-ornithine biosynthesis pathway from o
ketoglutarate, the intermediate of the TCA cycle. This part of L-ornithine synthesis is notable for its complicated
metabolic compartmentation, where key metabolites, such as L-glutamate, a-ketoglutarate and L-ornithine, are
synthesised in different organelle. Thus, the specific biosynthesis pathway as well as the intermediates
transportation/shutting should be co-ordinately optimized.
We started at managing the nature of compartmentalization to efficiently improve the L-ornithine titers (Fig.
2a, 2b and 2c). We first set out to enhance the L-ornithine synthesis pathway from L-glutamate in mitochondria.
CAR2 was initially deleted from strain M1b using a bipartite strategy (Erdeniz et al., 1997). Two overlapping
fragments of the kanMX resistance marker cassette flanked by loxP sites were amplified via PCR from plasmid
pUG6 (Giildener et al., 1996). Sequences upstream and downstream of CAR2 were also amplified. Due to
overlapping ends (introduced through the primer sequences) the GAf?2-upstream fragments could be fused to
the 5 ' kanMX fragment and the 3 ' kanMX fragment to the individual GAf?2-downstream fragments by fusion PCR
using the outer primers for amplification. The two overlapping PCR fragments thus generated for each gene
deletion were transformed into yeast using the lithium acetate method (Gietz and Woods, 2002). This resulted in
the stain ORN-E(KanMX). The strain with the CAR2 deletion displayed a slight increase in ornithine production
(Fig.lb). Next, the genes ARG5, 6 (EC. 1.2. 1.38; 2.7.2.8; SEQ ID NO: 3), ARG7 (EC 2.3.1.35; SEQ ID NO: 5) and
ARG8 (EC 2.6.1.11; SEQ ID NO: 4) were amplified from the genomic DNAof S. cerevisiae CEN.PK.113-5D and
constructed into the G01 plasmid according to MOPE strategy and DNA assembler as described in Example 1
above. The strain ORN-E(KanMX) was transformed with either two empty plasmids (pYX212 and p423GPD)
yielding strain M1c, or with an empty URA-based plasmid (pYX212) and G01 to yield strain M1cM2f.
Systematic overexpression of ARG5, 6, A ?G and ARG8 in strain M1cM2f, increased L-ornithine titers to 59
mg I 1, representing a 3 1 % increase as compared to the control (strain M1c)(Fig. 2d). This part of the pathway is
known as the acetylated derivatives cycle because the acetyl group that is added to L-glutamate in the first step
of the pathway is recycled via N-acetylglutamate generated in the fifth step. We speculated that if the activity of
the first step which is catalysed by N-acetyl-ornithine synthase (NAGS, encoding by ARG2 EC 2.3.1.1) was
increased, the further L-ornithine titers should improve. To overexpress ARG2 (SEQ ID NO: 2), this gene was
amplified from the genome of S. cerevisiae CEN.PK113-5D strain and cloned into a plasmid together with ARG5,
6, ARG7 and ARG8 using the MOPE strategy, resulting in plasmid G02. This plasmid was co-transformed into
strain ORN-E(KanMX) along with pYX212, resulting in strain M1cM2g. This strain produced 80 mg of L-
ornithine, leading to an 36% increasing as compared to the strain expressing only ARG5, 6, ARG7 and ARG8
(strain M1cM2f)(Fig. 2d). Indeed, while the ARG2 overexpression could improve the efficiency of initial step in the
said L-ornithine pathway, it also fulfils an anaplerotic role to replenish the pathway intermediates that are lost due
to degradation or cell division.
We also investigated whether overexpression of the transcription factor Gcn4p could improve L-ornithine
production by up-regulation of corresponding genes such as above mentioned ARG5, 6, ARG7 an ARG8 in L-
ornithine synthetic pathway. Thus, we used different-strength promoters to fine-tune expression of a truncated
version of GCN4 {tGCN4), in which residues 99-1 06 were truncated to circumvent the rapid degradation through
the ubiquitin pathway. No obvious difference was observed in the L-ornithine titers of most of these constructs,
although overexpression of GCN4 using the GPD1 promoter did result in a 16% increase in ornithine titers after
24 h of cultivation (Fig. 8).
Distinguished from L-ornithine synthesis in bacteria, L-ornithine is first synthesised in mitochondria and then
exported by Ort1 p to the cytosol for L-arginine biosynthesis in yeast and hence we assessed whether increasing
the expression level of ORT1 could further boost the L-ornithine titers. First, the KanMX gene was removed from
strain ORN-E(KanMX) by introduction of Cre-recombinase-mediated recombination between the two flanking
loxP sites using plasmid pSH47 as described previously (Giildener et al., 1996), followed by removal of pSH47
by plating of the strain on 5-FOA . The ORT1 (SEQ ID NO: 10) gene was then amplified from the genome of S.
cerevisiae CEN.PK113-5D strain and integrated into the genome, resulting in strain ORN-F. This strain was co-
transformed with pYX212 and G02, resulting in strain M1cM2h. This increased the L-ornithine titers to 11 5 mg I
representing a 44% increase as compared to the control strain (M1cM2g)(Fig. 2d).
We then engineered L-glutamate biosynthesis and its intracellular trafficking for precursor supply. We
speculated that improving the internal L-glutamate trafficking step could increase the glutamate flux to futher
increase L-ornithine synthesis. Thus, the glutamate uniporter/aspartate-glutamate exchanger encoding gene
AGC1 (SEQ ID NO: 11) was overexpressed in strain M1cM2h as described above, and L-ornithine titers in
resulting strain M1cM2k increased to 149 mg , which was a 30% increase as compared to strain M1cM2h (115
mg I 1) (Fig. 2d). Once again, the internal trafficking steps were proved to be rate limiting in metabolic pathways
and overexpressing related transporters could be efficient to boost pathway flux to chemicals of interest. Beside
the glutamate transportation, a-ketoglutamate transport from mitochondria to cytosol for glutamate synthesis was
also enhanced by overexpressing the mitochondrial α-ketoglutamate exporter Od p (strain M1cM2o). However,
we did not observe any substantial improvement in L-ornithine titers (Fig. 10). This result suggested that either
the Od p could not efficiently export α-ketoglutamate or that the synthesis of α-ketoglutamate could be rate
limiting.
After resolving the L-glutamate transportation, the L-glutamate biosynthesis might become limiting for L-
ornithine overproduction. There are three pathways that contribute to L-glutamate synthesis in S. cerevesiae. Two
pathways are mediated by two isoforms of glutamate dehydrogenase, encoded by GDH1 (EC: 1.4. 1.4; SEQ ID
NO: 6) and GDH3 (EC: 1.4. 1.4; SEQ ID NO: 7), while the third one catalyzed by combined activities of glutamine
synthetase (encoded by GLN1; EC:6.3. 1.2; SEQ ID NO: 8) and glutamate synthase (encoded by GLT1;
EC 1.4. 1.14; SEQ ID NO: 9). We then overexpressed the three pathways separately in strain M 1cM2k respectively,
resulting strain in M 1cM2l (GDH1), M 1cM2m (GDH3) and M 1cM2n (GLN1 and GLT1). Strain M 1cM2l
(overexpressing GDH1) displayed a further 16% increase in ornithine production, when compared to strain
M 1cM2k, and the final L-ornithine titer reached 173 mg (Fig. 2d). However, we could not see any further
improvement when either GDH3 (strain M 1cM2m) or GLN1 and GLT1 (strain M 1cM2n) were expressed. These
results indicated that Gdhl p is more efficient for synthesis of L-glutamate than Gdh3p and even the GS-GOGAT
system.
The separated compartmentalization of metabolites should hinder the substrate channeling for consecutive
enzyme catalysis. In our case, a-ketoglutarate (mitochondria), L-glutamate (cytoplasm) and L-ornithine
(mitochondria) are synthesized in different organelles. Thus, re-localization of these steps into same organelle
might be helpful for L-ornithine production. We first introduced the single cytosolic step of L-glutamate
biosynthesis into mitochondria by re-localizing the most efficient glutamate dehydrogenase Gdhl p into
mitochondria. Considering Gdh1 p is NADPH dependent and mitochondria is not rich in NADPH, we also set out
to target and overexpress Gdh2p (EC 1.4. 1.2) which is NADH dependent, into the mitochondria. Though the
reaction catalyzd by Gdh2p favours L-glutamate degradation, but not synthesis in S. cerevesiae, the high level of
a-ketoglutarate and NADH in mitochondria might reverse the reaction towards L-glutamate synthesis from o
ketoglutarate. Contrary to expectations, mitochondrial re-localization of Gdhl p (strain M 1cM2i) and Gdh2p
(M1 cM2j) decreased the L-ornithine titers significantly (Fig. 11) . The lack of increase of L-ornithine production by
mitochondrial Gdh2p targeting might be attributed to its role in L-glutamate degradation which reduced the
availability of the precursor for L-ornithine synthesis, while the decrease of L-ornithine production in mitochondrial
Gdhl p targeting might be caused by the absence of functional targeting, which even intervene in mitochondrial
function.
We then alternatively re-localized L-ornithine synthetic pathway to cytosol, where the precursor L-glutamate
is synthesized. We introduced a chimeric heterologous cytosollic L-ornithine synthetic pathway in strain M 1cM2q,
where the first two enzymes encoding genes argAEc (SEQ ID NO: 23) and argBEc (SEQ ID NO: 24) were from E.
coli and other three enzymes encoding genes argJcg (SEQ ID NO: 27), argCcg (SEQ ID NO: 25) and argDcg SEQ
ID NO: 26) were cloned from C. glutamicum. The successful complementation of L-arginine auxotrophic S.
cerevisiae strain with 0RT1 disruption (Fig. 12), demonstrated that the cytosolic pathway was functional to provide
the precursor L-ornithine for L-arginine biosynthesis. We also observed that M 1cM2q gave an 11% increase of L-
ornithine, as compared to strain M1cM2l to 192 mg in shake flask fermentation (Fig. 2d). These results
demonstrated re-localization of the complete pathway into the cytosol was helpful for L-ornithine production.
Example 4
'Crabtree negative' S. cerevisiae construction enables efficient carbon channeling to L-ornithine
After efficiently channelling a-ketoglutarate toward L-ornithine, we set out to enhance a-ketoglutarate supply
pathway by optimizing Module 3 . However, the optimization of this part will be more difficult in S. cerevisiae due
to the notable 'Crabtree effect', i.e. the major carbon flux is channeled to ethanol via aerobic-fermentation when
S. cerevisiae is growing exponentially on glucose aerobically. This 'Crabtree effect' actually compromised the
carbon flux to TCA cycle providing α-ketoglutarate during L-ornithine biosynthesis (Fig. 3a).
Previous studies showed that the TCA cycle flux was to some extent controlled by phosphorylation of
pyruvate dehydrogenase and that one mutation in the pyruvate dehydrogenase complex E 1 a subunit Pdalp
(EC1.2.4.1 ) can bypass the regulation (Oliveira et al. 2012). In this invention, we overexpressed both wild-type
and mutated PDA1 to drive more flux to L-ornithine synthesis. In addition, we overexpressed the potential
corresponding genes that catalyze steps from pyruvate to α-ketoglutarate, including one of the pyruvate
carboxylase isomers encoding gene PYC2 (EC:6.4.1.1), citrate synthase encoding gene CIT1 (EC:2.3.3.16),
aconitase encoding gene AC01 (EC 4.2.1.3) and isocitrate dehydrogenase encoding gene IDP1 (EC 1.1.1.42).
The strain M1cM2qM3a, carrying the overexpression of PDA1, PYC2, CIT1, AC01 and IDP1, had L-ornithine
titers of 245 mg , representing a 28% increase as compared to parent strain M1cM2q (Fig. 3d), and
overexpression of mutated mPDAI based on PYC2, CIT1, AC01, IDP1 (strain M1cM2qM3b) just had a slight
further L-ornithine increase to 264 mg (Fig. 3d) as compared to strain M1cM2qM3a. The detailed physiological
investigation showed that M1cM2qM3b and M1cM2qM3a exhibited approximately 2-fold increased L-
ornithine/glucose yield as compared to the parent, whereas there was no substantial difference when compared
with the control in terms of biomass yield and maximum specific growth rate. The ethanol yield on glucose made
no difference. These results demonstrated that the 'Crabtree effect' could not be substantially alleviated by directly
overexpressing the TCA cycle enzymes, but the metabolic flux of the TCA cycle could be improved at a smaller
extent.
If the 'Crabtree effect' was due to the limited capacity of the respiration chain and the overexpression of
NADH alternative oxidase (AOX) substantially alleviated the overflow to ethanol and if AOX overexpression up-
regulated almost every step of the TCA cycle, this may be helpful for increasing production of TCA cycle derived
chemicals.. We overexpressed AO from Hansenula anomala (HaAOXI) and also NDI1 (SEQ ID NO: 21)
encoding the internal NADH dehydrogenase, which mediated the delivery of the equivalents to the respiratory
chain. The overexpression of HaAOXI (strain M1cM2qM3c) enabled the L-ornithine titers to reach 258 mg ,
representing a 35% increase as compared the parent strain M1cM2q (Fig. 3d). Furthermore, combined
overexpression of NDI1 and HaAOXI further increased L-ornithine production to 278 mg (Fig. 3d). These
results indicated that NADH dehydrogenation was a rate limiting step in NADH oxidation, and overexpression of
alternative NADH oxidase was an efficient strategy to boost the TCA flux for the production of TCA derived amino
acids. It should be emphasized that the overexpression HaAOXI and NDI1 (strain M1cM2qM3d) increased the
L-ornithine production to the same level as boosting the TCA cycle's enzyme activity by direct overexpression of
related genes (strain M1cM2qM3b) (Fig. 3d).
Although aforementioned strategy had to some extent positive effect on L-ornithine production, the 'Crabtree
effect' needed further alleviation. Overexpression of ΜΤΗ1-∆ Τ (strain M1cM2qM3e) increased L-ornithine titers
up to 778 mg compared to the parent strain M1cM2q (Fig. 3d). It should also be emphasized that while the
- verexpression (M1dM2qM3e) strain produced no ethanol and had low glucose uptake of 0.2 g glucose
(g DCW)- h-1, the parent strain had ethanol production of 1.3 g ethanol (g DCW)- lv 1 and glucose uptake rate of
2.2 g glucose (g DCW)- lv 1 (Fig. 3e). These results demonstrated that alleviating the 'Crabtree effect' of S.
cerevisiae was an efficient strategy to boost L-ornithine production by enhancing TCA cycle flux.
We also assessed whether ODC attenuation might redirect more TCA flux to synthesis of L-glutamate, the
precursor of L-ornithine. However, attenuation of KGD2, encoding one of the components of the mitochondrial o
ketoglutarate dehydrogenase complex, decreased L-ornithine titers 10-folds (Fig. 13). KGD2 down-regulation
(Strain M1dM2qM3f) restored the glucose uptake of 2.2 g glucose (g DCW)- lv 1 and ethanol production of g
ethanol (g DCW)- h-1 compared to the parent strain of - verexpression.
Besides the molecular manipulation, we explored the possibility of alleviating the 'Crabtree effect' by using
an aerobic glucose-limited fed-batch strategy with strain M 1cM2qM3a, whose upstream TCA cycle was enhanced
as described above. Our engineered strain gave a final L-ornithine titer of 5.1 g , whereas the DCW was 56 g I-
(Fig. 4).
Example 5
'Urea cycle' engineering enables further L-ornithine titer improvement
S. cerevisiae has the potential to operate a urea cycle: arginase (encoded by CAR1; EC:3.5.3.1 ; SEQ ID NO:
1)) can degrade L-arginine into urea and L-ornithine. Early study showed that in the presence of L-arginine and
L-ornithine, ornithine carbamoyltransferase (OTC, Arg3p) and arginase (Carl p), both trimeric proteins, can form
the so-called 'epi-arginase' mode of regulation, i.e. a one-to-one complex in which arginase remains active but
OTC activity is inhibited. This regulation prevents the formation of an L-ornithine futile cycle when the biosynthesis
of L-arginine is repressed and the catabolism of L-arginine activated. Our previous result showed that the strain
with attenuated Arg3p still maintained 2/3 of the L-arginine intracellular concentration. It is speculated that
overexpression of Carlp could enable even lower intracellular L-arginine. CAR1 overexpression (strain
M1dM2qM3e) gave the final L-ornithine titers to 1041 mg , representing a further 34% increase as compared to
the parent strain M1cM2qM3e and 23-fold when compared with strain M1c (Fig. 3d). Our result indicated that
CAR1 overexpression pushed more flux into the L-ornithine synthesis cycle.
Example 6
Overexpression of the putrescine biosynthetic pathway in S. cerevisiae
To increase putrescine production, the gene 0AZ1, coding for the ornithine decarboxylase antizyme was
deleted from strain ORN-L(KanMX) and strain CEN.PK113-11C. First, the KanMX marker from ORN-L(KanMX)
was looped out by introduction of Cre-recombinase-mediated recombination between the two flanking loxP sites
using plasmid pSH47 as described previously (Giildener et al., 1996), followed by removal of pSH47 by plating
of the strain on 5-FOA, resulting in strain ORN-L . Next, 0AZ1 was deleted from ORN-L and CEN.PK113-11C
using a bipartite strategy (Erdeniz et al., 1997). Two overlapping fragments of the kanMX resistance marker
cassette flanked by loxP sites were amplified via PCR from plasmid pUG6 (Giildener et al., 1996). Sequences
upstream and downstream of 0AZ1 were also amplified. Due to overlapping ends (introduced through the primer
sequences) the O-AZi-upstream fragments could be fused to the 5 ' kanMX fragment and the 3 ' kanMX fragment
to the individual O-AZi-downstream fragments by fusion PCR using the outer primers for amplification. The two
overlapping PCR fragments thus generated for each gene deletion were transformed into yeast using the lithium
acetate method (Gietz and Woods, 2002). This resulted in strains PUT-A(KanMX) (expressing the ornithine
pathway) and WT-PUT-A(KanMX) (not-expressing the ornithine platform). Subsequent transformation of WT-
PUT-A(KanMX) with p426GPD and p423GPD resulted in strain WT-PUT1 . PUT-A(KanMX) was transformed with
plasmids p426GPD and G04, resulting in strain PUT-1 .
In parallel, following the same procedure, we also constructed the integration cassette for SPE1
overexpression which codes for ornithine decarboxylase (EC 4.1.1.17). SPE1 was amplified from S. cerevisiae
(CEN.PK113-11C) genome (SEQ ID NO: 29) and placed under the control of TEF1 promoter and PRM9t
terminator (Chen et al., 2012a) using fusion PCR procedures. The cassette was integrated to OAZ1 site of ORN-
L and CEN.PK113-11C, resulting in strains PUT-B(KanMX) and WT-PUT-B(KanMX), respectively. WT-PUT-
B(KanMX) was then transformed with plasmids p426GPD and p423GPD, resulting in strain WT-PUT2. PUT-
B(KanMX) was transformed with plasmids p426GPD and G04, resulting in strain PUT-2.
To further increase production of putrescine, the export of these polyamines can be increased by
overexpressing genes associated with polyamine export or deleting genes associated with polyamine uptake. To
increase putrescine production by S. cerevisiae, the gene TP01 (SEQ ID NO: 32) was amplified from the genome
of S. cerevisiae (CEN.PK11 3-11 C) using PCR. This gene was then cloned into p412GPD under the control of the
TDH3 promoter using standard cloning procedures, resulting in plasmid p412GPD -TP01. This plasmid was
transformed into strain WT-PUT-B(KanMX) together with plasmid p423GPD, resulting in strains WT-PUT3.
p412GPD -TP01 was also transformed into strain PUT-B(KanMX) together with the vector G04, resulting in
strain PUT3.
The resulting strains were cultivated in minimal media. In order to quantify polyamine production, samples
were treated as follows: cultivation sample was prepared by taking 1 ml of liquid culture. Cells were spun down
by centrifugation. The supernatant was directly used for derivatization. Cells were subject to Hot Water (HW)
Extraction. This procedure was adapted from (Canelas et al. 2009). Tubes containing 1 ml of demineralized water
were preheated in a water bath at 95-100 °C for 10 min. Then, the hot water was quickly poured over the cell
pellet; the mixture was immediately vortexed, and the sample was placed in the water bath. After 30 min, each
tube was placed on ice for 5 min. After centrifugation, the supernatant was directly used for derivatization. For the
accurate measurement of polyamine concentration, samples were diluted, if necessary, to give polyamine
concentration within the standard curve range. For derivatization, the procedure was adapted from (Kim et al.
2015). In brief, 0.25 ml of saturated NaHC03 solution and 0.5 ml of dansyl chloride solution (5 mg/ml in acetone)
were added to 0.5 ml of sample. Then the reaction mixture was incubated at 40°C for 1 h in the dark with
occasional shaking. The reaction was stopped by adding 0.1 ml 25% ammonium hydroxide. Samples filtered
through a 25 mm syringe filter (0.45 µηι Nylon) can be used for HPLC detection. The following chromatographic
condition are used: C18 (100 mm 4 . 6 mm i . d., 2.6 µηι, Phenomenex Kinetex), excitation wavelength 340nm,
emission wavelength 515nm, Sample injecting 10µ Ι, column temperature 40°C, Detector sensitivity 7, acquisition
starts at 3.4 min. The mobile phase is water and methanol with the speed of 1mL /min. The elution program is as
follows: 0-23 min 50% to 95% MeOH, 23-27 min 95% MeOH, 27-32 min 95% to 100% MeOH, 32-37 min 100%
to 50% MeOH.
Both intracellular and extracellular putrescine levels were quantified (Fig. 15). Levels of putrescine
significantly increased upon deletion of OAZ1, and increased further upon introduction of SPE1 (Fig. 15).
Furthermore, strains engineered for increased ornithine production (strains PUT1, PUT2 and PUT3) produced
significantly more putrescine compared to strains without any ornithine pathway modifications (Fig. 15), displaying
the benefits of the ornithine platform for polyamine production. In addition, a slight increase in putrescine levels
was observed for strains overexpressing the transporter TP01 (Fig. 15).
Example 7
Overexpression of the spermidine biosynthetic pathway in S. cerevisiae
To increase spermidine production by S. cerevisiae, the genes SPE2 (SEQ ID NO: 30) and SPE3 (SEQ ID
NO: 31), encoding S-adenosylmethionine decarboxylase (EC 4.1.1.50) and spermidine synthase (EC 2.5.1.16)
(respectively), were amplified from the genome of S. cerevisiae (CEN.PK113-11C) using PCR.
Following the same procedure, we also constructed the integration cassette for SPE3 overexpression which
codes for Spermidine synthase (EC 2.5.1.16). SPE3 was amplified from S. cerevisiae (CEN.PK11 3-11 C) genome
(SEQ ID NO: 31) and placed under the control of PGK1 promoter and pYX212t terminator using fusion PCR
procedures. SPE1 which codes for ornithine decarboxylase (EC 4.1.1.17) together with TEF1 promoter and
PRM9t terminator was also included in the same cassette. The cassette was integrated into OAZ1 site of ORN-
L, resulting in strain SPD-A(KanMX). Subsequent transformation of plasmid p426GPD and G04 resulted in strain
SPD1.
In parallel, following the same procedure, we also constructed the integration cassette for SPE2 (SEQ ID
NO: 30) encoding S-adenosylmethionine decarboxylase (EC 4.1.1.50). SPE2 was amplified from S. cerevisiae
(CEN.PK113-11C) genome (SEQ ID NO: 30) and placed under the control of TDH3 promoter and DIT1t terminator
using fusion PCR procedures. SPE1 which codes for ornithine decarboxylase (EC 4.1.1.17) together with TEF1
promoter and PRM9t terminator was also included in the same cassette. Also, SPE3 which was amplified from S.
cerevisiae (CEN.PK113-11C) genome (SEQ ID NO: 31) under the control of PGK1 promoter and pYX212t
terminator using fusion PCR procedures was as part of the integration cassette. The full cassette was integrated
into the OAZ1 site of ORN-L, resulting in strain SPD-B(KanMX). Subsequent transformation of this strain with
plasmids p426GPD and G04 resulted in strain SPD2.
The resulting strains were cultivated in minimal media and processed for spermidine quantification as
described in Example 6 above. Fig. 16 shows the modified strains to produce significantly more spermidine than
what is found in the control (CEN.PK113-11C) strain, with strain SPD2 producing the highest levels.
Example 8
Overexpression of an alternative pathway for spermidine production
In some bacterial species, spermidine can be produced via the condensation of L-aspartate semialdehyde
and putrescine via carboxynorspermidine dehydrogenase (CANSDH) yielding carboxyspermidine, followed by
decarboxylation by carboxnorspermidine decarboxylase (CANSDC). Genes encoding enzymes with these
activities can be expressed to facilitate spermidine production. CANSDH and CANSDC from several organisms
can be used. CjCANSDH (Cj0172c, SEQ ID NO: 46) and CjCANDC (Cj1515c, SEQ ID NO: 47) can be codon-
optimized based on sequences from Campylobacterjejuni. VcCANSDH (VC1624, SEQ ID NO: 48) and VcCANDC
(VC1623, SEQ ID NO: 49 can be codon-optimized based on sequences from Vibrio cholerae. BuCANSDH (Lys1,
SEQ ID NO: 50 and BuCANDC(nspC, SEQ ID NO: 51 can be codon-optimized based on sequences from
Bacteroides uniformis. Each pair of CANSDH and CANSDC can be cloned into the plasmid pYX212 under the
promoter of TPIp and PGK1p respectively by the standard Gibson Assembly protocols with a commercial Kit from
NEB. The resulting plasmids, YP1, YP2 and YP3 each encode a CANSDH and CANSDC from C. jejuni, V
cholerae and B. uniformis, respectively. These plasmids can be separately transformed into strain PUT-B(KanMX)
together with the vector G04 resulting in strains SPD-B1, SPD-B2 and SPD-B3, capable of producing high levels
of spermidine.
Example 9
Overexpression of the spermine biosynthetic pathway in S. cerevisiae
To increase spermine production in S. cerevisiae, the gene SPE1, which codes for ornithine decarboxylase
(EC 4.1.1.17), can be amplified from S. cerevisiae (CEN.PK113-11C) genome (SEQ ID NO: 29) and cloned into
vector pSP-GM1 under the control of a TEF1 promoter (Chen et al., 201 2a) using standard cloning procedures.
The former resulting in pSP-GM1 -SPE1 . The genes SPE2 (SEQ ID NO: 30) and SPE3 (SEQ ID NO: 3 1) , encoding
S-adenosylmethionine decarboxylase (EC 4.1.1.50) and spermidine synthase (EC 2.5.1.16) (respectively), can
be amplified from the genome of S. cerevisiae (CEN.PK113-11C) using PCR. SPE2 can be cloned into pSP-GM1-
SPE1 under the control of the PGK1 promoter using standard cloning procedures, resulting in plasmid pSP-GM1-
SPE12. SPE3 can be cloned into pSP-GM1 (Chen et al., 201 2a) under the control of a TEF1 promoter, resulting
in plasmid pSP-GM1-SPE3. The TEFp-SPE3-tADH1 cassette can amplified from pSP-GM1-SPE3 and cloned
into pSP-GM1-SPE12 in reverse orientation, resulting in plasmid pSP-GM1-SPD (expressing the genes SPE1,
SPE2 and SPE3). Next, the gene SPE4 (SEQ ID NO: 43), encoding spermine synthase (EC 2.5.1.22) can be
amplified from the genome of S. cerevisiae (CEN.PK11 3-11 C) using PCR and cloned into pSP-GM1-SPE3 under
the control of the PGK1 promoter, resulting in plasmid pSP-GM1-SPE34. The cassette encoding tCYC1-SPE4-
PGK1p-pTEF1-SPE3-tADH1 can be then amplified from pSP-GM1-SPE34 and cloned into pSP-GM1-SPE12 in
reverse orientation, resulting in plasmid pSP-GM1-SPM (expressing the genes SPE1, SPE2, SPE3 and SPE4).
pSP-GM1-SPM can be transformed into strain PUT-A(KanMX) together with the vector G04 resulting in strain
AKYSPM1, capable of producing high levels of spermine.
Example 10
Increased export of polyamines in S. cerevisiae
To further increase production of putrescine, spermidine or spermine, the export of these polyamines can be
increased by deleting genes associated with polyamine uptake. The AGP2, SAM3 and DUR3 genes, which are
involved in polyamine uptake, can be deleted consecutively from strain PUT-B(KanMX )as described in Example
6 above, resulting in strain AKYDOAZ-Trans2. Next, AKYDOAZ-Trans2 can be co-transformed with plasmids
pSP-GM1-PUT and G04, resulting in strain AKYPUT2, capable of producing high levels of putrescine. The strain
AKYDOAZ-Trans2 can also be transformed with the plasmids pSP-GM1-SPD and G04, resulting in strain
AKYSPD2, capable of producing high levels of spermidine. The strain AKYDOAZ-Trans3 can also transformed
with the plasmids pSP-GM1-SPM and G04, resulting in strain AKYSPM2, capable of producing high levels of
spermine.
Example 11
Production of agmatine in S. cerevisiae
To create a strain capable of producing agmatine, the gene encoding arginase (CAR1) can be deleted from
strain CEN. PK1 13-1 1C using KanMX-bipartite deletion strategy as described in Example 6, resulting in strain
AKYDCAR1 . Next, the genes encoding for ornithine carbamoyltransferase (EC 2 .1.33), argininosuccinate
synthase (EC 6.3.4.5) and argininosuccinate lyase (EC 4.3.2. 1) , encoded by ARG3, ARG1 and ARG4 (SEQ ID
NO: 34-36) can be amplified from the genome of S. cerevisiae (CEN. PK1 13-1 1C). ARG3 and ARG1 can be cloned
into pSP-GM1 under the control of the TEF1 and PGK1 promoters, resulting in plasmid pSP-GM1 -ARGA. ARG4
can be cloned into pSP-GM1 , under the control of the TEF1 promoter, resulting in plasmid pSP-GM1 -ARGB. The
TEF1p-ARG4-tADH1 cassette can be amplified from pSP-GM1 -ARGB, and cloned in reverse orientation into
plasmid pSP-GM1 -ARGA, resulting in plasmid pSP-GM1 -ARGC (expressing ARG3, ARG1 an ARG4). The gene
encoding arginine decarboxylase (EC 4 .1.1.19) {speA) (SEQ ID NO: 37) can be amplified from E. coli (DH5a) and
cloned into plasmid plYC04 (Chen et al., 201 2b) under the control of the TEF1 promoter, resulting in plasmid
plYC04-speA. The plasmids pSP-GM1 -ARGC and plYC04-speA can be co-transformed into strain AKYDCAR1 ,
resulting in strain AKYAGM1, capable of producing agmatine.
To create a yeast strain capable of converting agmatine to spermidine, a bidirectional PGK1p-TEF1p
promoter cassette can be amplified from plasmid pSP-GM1 via PCR. Next, the genes encoding S-
adenosylmethionine decarboxylase (SP£2) (SEQ ID NO: 30) and spermidine synthase (SPE3) (SEQ ID NO: 3 1)
can be amplified from the S. cerevisiae (CEN.PK1 13-1 1C) genome using overhang-containing primers that allow
fusion of these genes to the PGK1p-TEF1p cassette {SPE2 under the control of TEF1p and SPE3 under the
control of PGK1p). The SPE3-PGK1p-TEF1p-SPE2 cassette can then cloned into vector pXI-5 (Mikkelsen et al.,
201 2), resulting in vector pXI-5-SPE32, allowing the targeting of these genes into the Chr XI: 11779. .118967
region of the yeast genome. This vector can be linearized and transformed into strain AKYDCAR1 , followed by
looping-out of the URA3 marker, resulting in strain AKYAGM2 (containing the two integrated genes).
The gene encoding agmatinase (EC 3.5.3. 11) speE (SEQ ID NO: 38) can be amplified from E. coli and
cloned into plYC04-speA under the control of the PGK promoter, resulting in plasmid plYC04-speAB. The
plasmids plYC04-speASB and pSP-GM1 -ARGC can be co-transformed into strain AKYAGM2, resulting in strain
AKYAGM3, capable of converting agmatine into putrescine and spermidine.
To create a strain capable of producing spermine via the agmatine route, the PGK1p-SPE4 cassette can be
amplified from plasmid pSP-GM1 -SPE34 and cloned into into vector pX-4 (Mikkelsen et al., 201 2), resulting in
vector pX-4-SPE4, capable of targeting SPE4 to the Chr X : 236336. .23731 0 region of the yeast genome. This
vector was linearized and transformed into strain AKYAGM2, followed by looping out of the URA3 marker,
resulting in strain AKYAGM4.
The plasmids plYC04-speAB and pSP-GM1 -ARGC can be co-transformed into strain AKYAGM4, resulting
in strain AKYAGM5, capable of converting agmatine into putrescine, spermidine and spermine.
Example 12
Production of spermidine/spermine in Escherichia coli
Modifications in E. coli WL3110 (orig. K12 W3110 (CGSC, Coli Genetic Stock Center); (Park et al. 2007)) to
increase ornithine and putrescine production respectively can be implemented as described in Quian et al. (2009).
For example these comprise enhancing precursor supply (deletion of argl gene), inactivating putrescine
degradation and utilization pathways (deletion of speG; puuPA, argR) and deletion of rpoS, a stress responsive
polymerase sigma factor. Also genes coding for ornithine decarboxylase converting ornithine to putrescine and
ornithine biosynthetic genes [argC-E] can be overexpressed either through plasmids or chromosomal integration.
This platform strain can be transformed with either plasmids for overexpression of endogenous or heterologous
speE (E.C.: 2.5.1.16; SEQ ID NO: 37) and speD (EC 4 .1.1.50; SEQ ID NO: 39) genes. For example the expression
vector pTRC-LIC (Plasmid #62343; Addgene (Massachusetts, USA)) is used to systematically co-express the
mentioned genes under control of the strong Ptrc promoter. Cloning is done via amplification of target genes
through 30 bp overhang primers to the expression vector (Ptrc promoter control) and carried out via the Gibson
cloning approach (Gibson ef al. 2009). Alternatively chromosomal replacement of promoters of these genes with
a constitutive active strong hybrid-promoter like Ptrc can be performed. To facilitate increased spermidine export,
genes coding for exporters e.g. the mdtJI complex genes (SEQ ID NO: 40-41) can be overexpressed through
plasmid based expression or promoter exchange as described above. The gene coding for the spermidine
exporter bit from B. subtilis (SEQ ID NO: 42) can be amplified from B. subtilis genomic DNA and also
hetorologously expressed under E. coli promoter control (e.g. Ptrc). For the tailored production of spermine
heterologous spermine synthases (E.C. 2.5.1.22) from eukaryotic sources are expressed e.g. derived from S.
cerevisiae, Triticum aestivum, Oryza sativa, Glycine max, Citrus sinesis, Homo sapiens. For example spermine
synthase gene SPE4 (Gl: 3201942; SE ID NO: 43) can be amplified from S. cerevisiae genomic DNA
(CEN.PK113-11C) using PCR with 30 bp overhang primers and cloned via Gibson cloning (Gibson ef al. 2009)
into expression vector pTRC.
Example 13
Production of spermidine/spermine in Corynebacterium glutanicum
Modifications to increase ornithine production in C. glutamicum strain ATCC 13032 can be performed as
described in Kim et al. (2015): deletion of proB and argF (block competing pathways); deletion of argR gene
(repressor of the L-arginine operon); overexpression of argCJBD from C. glutanicum ATCC 21831; start codon
change of pgi and zwf (enrichment of NADPH pool), replacing native promoter of tkt operon with a strong sod
promoter. For increased putrescine production the strain can be further engineered as described in Schneider et
al. (2010): The strain was modified with overexpression of ornithine decarboxylase speC (EC 4.1.1.19; SEQ ID
NO: 44) from E. coli and chromosomal deletion of carbamoyl-transferase argF. For increased spermidine
production endogenous spermidine synthase gene speE (SEQ ID NO: 45) can be either overexpressed through
plasmid based expression or intregrating of multiple copies into the genome. For example, E. coli- C. glutanicum
shuttle vector pMS2 (ATTC®67189TM) with kanamycin as selective marker is used for plasmid based
overexpression of heterologous speD. For plasmid construction two fragments can be amplified: fragment
containing the Ptac promoter and lacl gene derived from pTAC-MAT-Tag®-1 (Sigma) and the speD gene from E.
coli genomic DNA (SEQ ID NO: 39). 30 bp overhanging primers can be used to amplify fragments and
subsequently cloned via Gibson cloning (Gibson e al. 2009) into the shuttle vector pMS2 with speD under Ptac
control creating the expression vector pFDAMS2. After transformation into modified C. glutanicum strain ATCC
13032 strain (see above) it can be cultivated as described in Schneider et al. 2010. To facilitate increased
spermidine export, genes coding for exporters e.g. mdtJI from E. coli (SEQ ID NO: 40-41) or bit from B. subtilis
(SEQ ID NO: 42) can be amplified from E. coli genomic DNA respective B. subtilis genomic DNA and also
heterologously expressed in C. glutanicum as described above. For the tailored production of spermine
heterologous spermine synthases (E.C. 2.5.1.22) from eukaryotic sources can be expressed.via plasmid-based
expression (see above). For example spermine synthases can be derived from S. cerevisiae [Spe4, G : 3201942;
SEQ D NO: 43), Triticum aestivum, Oryza sativa, Glycine max, Cit s sinesis, Homo sapiens.
Table 1: Background strains constructed for ornithine production.
Strain name Genotype
ORN-A MATa SUC2 MAL2-8c ura3-52 his3-M PARGS::PHXTI
ORN-B MATa SUC2 MAL2-8c ura3-52 his3-M PARGS::PKEX2
ORN-
MATa SUC2 MAL2-8c ura3-52 his3-Al PARG3::PKEX2 car2 ::LoxP-KanMX-LoxP
E(KanMX)
ORN- MATa SUC2 MAL2-8c ura3-52 his3-Al PARG3::PKEX2 car2 ::LoxP-KanMX-LoxP-
F(KanMX) PTPI-ORT 1-TPYX212
ORN- MATa SUC2 MAL2-8c ura3-52 his3-Al PARG3::PKEX2 car2 ::LoxP-KanMX-LoxP-
G(KanMX) TcTci -AGC1-PtHXTi-PTPi-ORT1-TPYX2i2
ORN-F MATa SUC2 MAL2-8c ura3-52 his3-Al PARG3 P EX2 car2 ::LoxP-P TPi-ORT1-TpYxm
MATa SUC2 MAL2-8c ura3-52 his3-Al PARG3::PKEX2 car2 ::LoxP-Tcrci-AGC1-
ORN-G
PtHXTi-Prpi -ORT1-TpYX2i2
ORN- MATa SUC2 MAL2-8c ura3-52 his3-Al P ARG3 P EX2 car2 ::LoxP-P TPi-ORT1-TpYxm
H(KanMX) ura3:: LoxP-KanMX-LoxP-PTEFi-GDH1-T D iTi
MATa SUC2 MAL2-8c ura3-52 his3-Al P ARG3 P EX2 car2 ::LoxP-P TPi-ORT1-TpYxm
ORN-l(KanMX)
ura3:: LoxP-KanMX-LoxP-TTDH2-ODC1-PpGKi-PTEFi-GDH1-TDiTi
ORN- MATa SUC2 MAL2-8c ura3-52 his3-Al PARG3::PKEX2 car2::LoxP-PTPI-ORT1-
J(KanMX) TpYX212 ura3:: LoxP-KanMX-LoxP-PTEF1-MLS-GDH1-TDIT1
ORN- MATa SUC2 MAL2-8c ura3-52 his3-Al PARG3::PKEX2 car2::LoxP-PTPI-ORT1-
K(KanMX) TpYX212 ura3:: LoxP-KanMX-LoxP-PTEF1-MLS-GDH2-TDIT1
MATa SUC2 MAL2-8c ura3-52 his3-Al PARG3::PKEX2 car2::LoxP-PTPI-ORT1-
ORN-J
TpYX212 ura3:: LoxP-PTEF1-MLS-GDH1-TDIT1
ORN- MATa SUC2 MAL2-8c ura3-52 his3-Al PARG3 ::PKEX2car2::LoxP-Tcrci-AGC1-
L(KanMX) PtHXTi-Prpi -ORT1-TpYX2i2ura3:: LoxP-KanMX-LoxP-PTEF1-GDH1-TDIT1
ORN- MATa SUC2 MAL2-8c ura3-52 his3-M PARG3::PKEX2 car2::LoxP-Tcrci-AGC1-
M(KanMX) PtHXTi-PTPi -ORT1-TpYX2i2 ura3:: LoxP-KanMX-LoxP-PTEF1-GDH3-TDIT1
MATa SUC2 MAL2-8c ura3-52 his3-M PARG3 ::PKEX2 car2::LoxP-TcTci-AGC1-
ORN-
PtHXTi-PTPi -ORT1-T PYX2i2ura3:: LoxP-KanMX-LoxP-TTDH2-ODC1-PPGK1-
N(KanMX)
PTEF1-GDH3-TDIT1
MATa SUC2 MAL2-8c ura3-52 his3-M PARG3 ::PKEX2 car2::LoxP-Tcrci-AGC1-
ORN-
PtHXTi-PTPi -ORT1-T PYX2i2ura3:: LoxP-KanMX-LoxP-TTDH2-ODC1-PPGK1-
O(KanMX)
PTEF1-GDH1-TDIT1
ORN- MATa SUC2 MAL2-8c ura3-52 his3-M PARG3::PKEX2 car2::LoxP-Tcrci-AGC1-
P(KanMX) PtHXTi-PTPi -ORT1-TpYX2i2 YPRT3:: LoxP-KanMX-LoxP-PTEF1-AOX1-TPRM9





ORN- MATa SUC2 MAL2-8c ura3-52 his3 -Al PARG3 ::PKEX2 car2::LoxP-TcTci-AGC1-
R(KanMX) PtHXTi-PTPi -ORT1-T PYX2i2 ura3:: LoxP-KanMX-LoxP-PTEF1-MLS-GDH1-TDIT1
MATa SUC2 MAL2-8c ura3-52 his3 -Al PARG3 ::PKEX2 car2::LoxP-Tcrci-AGC1-
ORN-L
PtHXTi-Prpi -ORT1-TpYX2i2 ura3:: LoxP-PTEF1-GDH1-TDIT1
MATa SUC2 MAL2-8c ura3-52 his3 -Al PARG3 ::PKEX2 car2::LoxP-TcTci-AGC1-
ORN-0
PtHXTi-PTPi -ORT1-T PYX2i2ura3:: LoxP-TTDH2-ODC1-PPGK1-PTEF1-GDH1-TDIT1
MATa SUC2 MAL2-8c ura3-52 his3 -Al PARG3 ::PKEX2 car2::LoxP-Tcrci-AGC1-
ORN-
PtHXTi-PTPi -ORT1-TpYX2i2 ura3:: LoxP-PTEF1-GDH1-TDIT1 kgd2:: LoxP-KanMX-
S(KanMX)
LoxP
MATa SUC2 MAL2-8c ura3-52 his3 -Al PARG3::PKEX2 car2::LoxP-Tcrci-AGC1-
ORN-
PtHXTi-PTPi -ORT1-TpYX2i2 ura3:: LoxP-PTEF1-GDH1-TDIT1 kgd2:: LoxP-KanMX-
T(KanMX)
LoxP-TPRM9t-MTH1-PTEF1
MATa SUC2 MAL2-8c ura3-52 his3 -Al PARG3::PKEX2 car2::LoxP-Tcrci-AGC1-
ORN-
PtHXTi-PTPi -ORT1-TpYX2i2 ura3:: LoxP-PTEF1-GDH1-TDIT1 kgd2:: LoxP-KanMX-
U(KanMX)
LoxP-TPRM9t-AOX1-PTEF1
MATa SUC2 MAL2-8c ura3-52 his3-M PARG3::PKEX2 car2::LoxP-Tcrci-AGC1-
ORN-
25 PtHXTi-PTPi -ORT1-T PYX2i2 ura3:: LoxP-PTEF1-GDH1-TDIT1 YPRT 3:: LoxP-KanMX-
V(KanMX)
LoxP-PTEF1-MTH1-TPRM9
MATa SUC2 MAL2-8c ura3-52 his3-M PARG3::PKEX2 car2::LoxP-Tcrci-AGC1-
ORN-
26 PtHXTi-PTPi -ORT1-T PYX2i2 ura3:: LoxP-PTEF1-GDH1-TDIT1 YPRT 3:: LoxP-KanMX-
WN(KanMX)
LoxP-PTEF1-AOX1-TPRM9
MATa SUC2 MAL2-8c ura3-52 his3-M PARG3::PKEX2 car2 ::LoxP-Tcrci-AGC1-
ORN-
27 PtHXTi-PTPi -ORT1-TpYX2i2 ura3:: LoxP-PTEF1-GDH1-TDIT1 YPRT 3:: LoxP-KanMX-
W(KanMX)
LoxP-PTEF1-AOX1-TPRM9
MATa SUC2 MAL2-8c ura3-52 his3-M PARG3::PKEX2 car2::LoxP-Tcrci-AGC1-
ORN-
28 PtHXTi-PTPi -ORT1-T PYX2i2ura3:: LoxP-TTDH2-ODC1-PPGK1-PTEF1-GDH1-TDIT1
X(KanMX)
YPRr3:: LoxP-KanMX-LoxP-PTEF1-AOX1-TPRM9





MATa SUC2 MAL2-8c ura3-52 his3-Al PARG3::PKEX2car2::LoxP-TcTci-AGC1-
ORN-




3 1 MATa ORT1A
CEN.PK
CEN.PK113-
32 MATa SUC2 MAL2-8 ura3-52 his3-Al
11C
Table 2 : Strains used for module and full ornithine pathway optimization
P
M1a M1a Null Null Null Null ORN-A pYX212 p423GPD
ARG3
P









































































M1cM2t M1c ARG3; M2t Null Null pYX212
tGCN4 E(KanMX) tGCN4
CAR2A
P argAEc; PDA1 ;
M1cM2qM3 ORN-











M1cM2qM3 argDcg; 1;AC ORN-
M1c ARG3; M2q M3b Y05 G04








M1cM2qM3 argDcg; HcAO ORN-
M1c ARG3; M2q M3c pYX212 G04







P argCcg; HcAO ORN-
M1cM2qM3
M1c ARG3; M2q argDcg; M3d X 1; WN(KanMX pYX212 G04
d



























ARG3; argDcg; ORN- TPIp-
M1dM2q M1d M2q Null Null G04

















M1dM2qM3 ARG3; argDcg; ORN- TPIp-
32 M1d M2q M3e tMTH1 G04







ARG3; argDcg; ORN- TPIp-
33 M1dM2qM3f M1d M2q M3f G04





34 Null Null Null Null Null Null pYX212 G04
T1) CEN.PK
Table 3 : List of strains used for polyamine production
Strain name Background genotype Plasmids
PUT-A(KanMX) ORN-LAoaz1 None
WT-PUT- CEN.PK113-11C Aoaz1 None
A(KanMX)
PUT1 ORN-LAoaz1 p426GPD, G04
WT-PUT1 CEN.PK113-11C Aoaz1 p426GPD, p423GPD
PUT-B(KanMX) ORN-L Aoazl SPE1 none
WT-PUT- CEN.PK113-11C Aoaz1 SPE1 none
B(KanMX)
PUT2 ORN-L Aoazl SPE1 p426GPD , G04
WT-PUT2 CEN.PK113-11C Aoaz1 SPE1 p426GPD, p423GPD
PUT3 ORN-L Aoazl SPE1 P412GPD-TP01. G04
WT-PUT3 CEN.PK113-11C Aoaz1 SPE1 P412GPD-TP01, p423GPD
SPD-A(KanMX) ORN-L Aoazl SPE1 SPE3 none
SPD1 ORN-L Aoazl SPE1 SPE3 p426GPD, G04
SPD2 ORN-L Aoazl SPE1 SPE3 SPE2 p426GPD, G04
SPD-B(KanMX) ORN-L Aoazl SPE1 SPE3 SPE2 none
SPD-B1 ORN-L Aoazl SPE1 YP1. G04
SPD-B2 ORN-L Aoazl SPE1 YP2, G04
SPD-B3 ORN-L Aoazl SPE1 YP3, G04
AKYSPM1 ORN-V(KanMX) Aoazl pSP-GM1-SPM1, G04
AKYDOAZ-Transl AKYDOAZ TP01 TP05 none
AKYDOAZ-Trans2 PUT-A(KanMX) Asam3 Adur3 none
AKYPUT2 AKYDOAZ TP01 TP05 Asam3 pSP-GM1-PUT, G04
Adur3
AKYSPD2 AKYDOAZ TP01 TP05 Asam3 pSP-GM1-SPD, G04
Adur3
AKYSPM2 AKYDOAZ TP01 TP05 Asam3 pSP-GM1-SPM, G04
Adur3
AKYDCAR1 CEN.PK113-11C ca none
AKYAGM1 CEN.PK113-11C car pSP-GMI-ARGC, plYC04-speA
AKYAGM2 CEN.PK113-11C Acarl SPE2
SPE3
AKYAGM3 CEN.PK113-11C Acarl SPE2 pSP-GMI-ARGC, plYC04-speAB
SPE3
AKYAGM4 CEN.PK113-11C Acarl SPE2
SPE3 SPE4
AKYAGM5 CEN.PK113-11C Acarl SPE2 pSP-GMI-ARGC, plYC04-speAB
SPE3 SPE4
C. glutanicum Kalinowski et al . (2003) Background strain for
ATCC 13032 spermidine/spermine production in C.
glutanicum
E. coli WL31 10
orig. K12 W3110 (CGSC, Coli Background strain for
Genetic Stock Center); (Park et al. spermidine/spermine production in E.
2007)) coli
Table 4 : Plasmids used in this study
Plasmid/Alias Skeleton
No Genes Insert Marker Reference
Name Vector
1 G01 ARG5,6;ARG7;ARG8 p423GPD HIS3 This Study
2 G02 ARG5,6 ARG7; ARG8; ARG2 p423GPD HIS3 This Study
3 G03 ARG5,6 ARG7; ARG8; ARG2; CAR1 p423GPD HIS3 This Study
4 G04 argBEc; argAE, c argCc g: argDc g; argJcg p423GPD HIS3 This Study
5 Y01 GLN1; GLT1 pYX212 URA3 This Study
6 Y02 PYC2;CIT1; IDP1 pYX212 URA3 This Study
7 Y03 GLN1;GLT1; PYC2; CIT1; IDP1 pYX212 URA3 This Study
8 Y04 PDA1;AC02 ;PYC2; CIT1; IDP1 pYX212 URA3 This Study
9 Y05 mPDA1;AC02; PYC2; CIT1; IDP1 pYX212 URA3 This Study
pSPGM1-ARG2 ARG2 pSPGMI URA3 This Study
pSPGMI-
ARG5,6 pSPGMI URA3 This Study
ARG5.6
pSPGM1-ARG7 ARG7 pSPGMI URA3 This Study
pYX212-
MLS-argBcg pYX212 URA3 This Study
MLSargBcg
pYX212-MLS-
MLS-argJcg pYX212 URA3 This Study
argJcg
PADH1- tGCN4 tGCN4 p423ADH HIS3 This Study
PTEF1- tGCN4 tGCN4 p423TEF HIS3 This Study
PGPD1- tGCN4 tGCN4 p423GPD HIS3 This Study
(Johansson
TPIp-CAR1 CAR1 pYX212 URA3 et al.,
2014)
pRS416-PDA1 (Oliviera et
PDA1 [S313A] pRS416 URA3
[S313A] al., 2012)
(Oliviera et
pRS416-PDA1 PDA1 pRS416 URA3
al., 2012)
pSP-GM1-SPE1 PTEFI-SPE1 pSP-GM1 URA3 This study
pSP-GM1-SPE12 PTEFI-SPE 1, PPGKI-SPE2 pSP-GM1 URA3 This study
pSP-GM1-SPE3 PTEFI-SPE3 pSP-GM1 URA3 This study
pSP-GM1-SPD PTEFI-SPE 1, PPGKI-SPE2, PTEFI-SPE3 pSP-GM1 URA3 This study
pSP-GM1-SPE34 PTEFI-SPE3, PPGKI-SPE4 pSP-GM1 URA3 This study
PTEFI-SPE 1, PPGKI-SPE2, PTEFI-SPE3,
pSP-GM1-SPM pSP-GM1 URA3 This study
PPGKI-SPE4
pXI-3-TP015 PTEFI-TP01, PPGKI-TP05 pXI-3 URA3 This study
pSP-GM1-ARGA PTEFI-ARG3, PPGKI-ARG1 pSP-GM1 URA3 This study
pSP-GM1-ARGB PTEFI-ARG10, PPGKI-ARG4 pSP-GM1 URA3 This study
PTEFI-ARG3, PPGKI-ARG1
pSP-GM1-ARGC pSP-GM1 URA3 This study
PTEFI-ARG10, PPGKI-ARG4
plYC04-speA PrEFi -speA plYC04 HIS3 This study
PTEFI-SPE2, PPGKI-SPE3
pXI-5-SPE32 pXI-5 URA3 This study
PrEFi -speA, PpGKi -speB
plYC04-speAB plYC04 HIS3 This study
pX-4-SPE4 PTEFI-SPE4 pX-4 URA3 This study
pSP-GM1 Episomal backbone URA3 (Chen et
al., 2012a)
plYC04 Episomal backbone HIS3 (Chen et
al., 2012b)
pXI-3 (Mikkelsen
Integrative backbone URA3 et al.,
2012)
pXI-5 (Mikkelsen
Integrative backbone URA3 et al.,
2012)
pX-4 (Mikkelsen
Integrative backbone URA3 et al.,
2012)
pMS2 shuttle vector US Patent
ampR, kanR
ATTC®67189TM E. coli-C. glutanicum 4,920,054
pTAC-MAT-Tag®- Rosenberg
1 (Sigma) La , tac promoter amplification ampR et al.
(1987).
pFDAMS2 Episomal expression vector for C. Example
pMS2 ampR
glutanicum 11
(fac promoter controk target gene (e.g.
speD)
pTRC-LIC GenBank
Episomal expression vector for E. coli;
pTRC99a ampR Accession:











pTPOI TDH3p -TP01- CYC1t p426GPD URA3 This study
YP1 (TPIp-C/'C/4SDH-FBA1t)+(PGK1 p-
pYX212 URA3 This study
CjCASDC-CYCU)
YP2 (TPIp-VcC/4SDtf-FBA1t)+(PGK1p-
pYX212 URA3 This study
VcCASDC-CYCU)
YP3 (TPIp-BivC/4SDtf-FBA1t)+(PGK1p-
pYX212 URA3 This study
BuCASDC-CYCU)
REFERENCES
Avalos JL, Fink GR, Stephanopoulos G (2013) Compartmentalization of metabolic pathways in yeast
mitochondria improves the production of branched-chain alcohols. Nat Biotechnol 3 1(4):335-341
doi:10.1038/nbt.2509
Canelas, A . B., et al. (2009). "Quantitative Evaluation of Intracellular Metabolite Extraction Techniques for
Yeast Metabolomics." Anal. Chem. 8 1 ( 17): 7379-7389.
Chen, Y., Partow, S., Scalcinati, G., Siewers, V., Nielsen, J., 2012a. Enhancing the copy number of
episomal plasmids in Saccharomyces cerevisiae for improved protein production. FEMS Yeast Res. 12, 598-
607.
Chen, Y , Daviet, L , Schalk, M, Siewers, V, Nielsen, J., 2012b. Establishing a platform cell factory through
engineering of yeast Acetyl-CoA metabolism. Metab Eng. 15:48-54.
Chinard, F. P. Photometric estimation of proline and ornithine. J. Biol. Chem. 199, 91-95(1952).
Choi H, Kyeong HH, Choi JM, Kim HS. 2014. Rational design of ornithine decarboxylase with high catalytic
activity for the production of putrescine. Appl Microbiol Biotechnol. 98(17)7483-90
Erdeniz, N., Mortensen, U.H., Rothstein, R., 1997. Cloning-free PCR based allele replacement methods.
Genome Res. 7, 1174-1183.
Flagfeldt, DB., Siewers, V., Huang, L . & Nielsen, J. Characterization of chromosomal integration sites for
heterologous gene expression in Saccharomyces cerevisiae. Yeast 26, 545-551 (2009).
Gietz, R.D., Woods, R.A., 2002. Transformation of yeast by lithium acetate/single-stranded carrier
DNA/polyethylene glycol method. Meth. Enzymol. 350, 87-96.
Giildener, U., Heck, S., Fiedler, T., Beinhauer, J., Hegemann, J.H., 1996. A new efficient gene disruption
cassette for repeated use in budding yeast. Nucleic Acids Res. 24, 2519-2524.
Hwang G-H, Cho J-Y (2012) Implication of gluconate kinase activity in l-ornithine biosynthesis in
Corynebacterium glutamicum. J Ind Microbiol Biotechnol 39(1 2):1 869-1 874 doi: 10 .1007/s1 0295-01 2-1 197-7
Hwang G-H, Cho J-Y (2014) Enhancement of l-ornithine production by disruption of three genes encoding
putative oxidoreductases in Corynebacterium glutamicum. J Ind Microbiol Biotechnol 4 1(3):573-578
doi: 10.1007 /S1 0295-01 3-1 398-8
Hwang JH, Hwang GH, Cho JY (2008) Effect of increased glutamate availability on L-ornithine production
in Corynebacterium glutamicum. J Microbiol Biotechnol 18(4)704-710
Jiang L-Y, Zhang Y-Y, Li Z, Liu J-Z (2013a) Metabolic engineering of Corynebacterium glutamicum for
increasing the production of l-ornithine by increasing NADPH availability. J Ind Microbiol Biotechnol
40(1 0): 1143-1 15 1 doi: 10 .1007/s1 0295-01 3-1 306-2
Jiang LY, Chen SG, Zhang YY, Liu JZ (2013b) Metabolic evolution of Corynebacterium glutamicum for
increased production of L-ornithine. BMC Biotechnol 13:1 1 doi: 10. 1186/1472-6750-13-47
Johansson N1, Persson KO, Quehl P, Norbeck J, Larsson C. (2014). Ethylene production in relation to
nitrogen metabolism in Saccharomyces cerevisiae. FEMS Yeast Res.14(7):1 110-8.
Kalinowski, Jorn, et al. "The complete Corynebacterium glutamicum ATCC 13032 genome sequence and
its impact on the production of L-aspartate-derived amino acids and vitamins." Journal of biotechnology 104.1
(2003): 5-25.
Kim SY, Lee J, Lee SY (2014) Metabolic engineering of Corynebacterium glutamicum for the production of
L-ornithine. Biotechnol Bioeng:n/a-n/a doi: 10.1 002/bit.25440
Kim, S.-K., etal. (2015). "Enhanced tolerance ofSaccharomyces cerevisiae to multiple lignocellulose-derived
inhibitors through modulation of spermidine contents." Metabolic Engineering 29: 46-5
Mikkelsen MD, Buron LD, Salomonsen B, Olsen CE, Hansen BG, Mortensen UH, Halkier BA. 2012.
Microbial production of indolylglucosinolate through engineering of a multi-gene pathway in a versatile yeast
expression platform. Metab Eng. 14(2): 104-11.
Mumberg D 1, Miiller R, Funk M . Yeast vectors for the controlled expression of heterologous proteins in
different genetic backgrounds. Gene. 1995; 156(1): 119-22.
Oliveira AP, Ludwig C, Picotti P, Kogadeeva M, Aebersold R, Sauer U (201 2) Regulation of yeast central
metabolism by enzyme phosphorylation, vol 8,
Oud B, Flores C-L, Gancedo C, Zhang X, Trueheart J, Daran J-M, Pronk J, van Maris A (2012) An internal
deletion in MTH1 enables growth on glucose of pyruvate-decarboxylase negative, non-fermentative
Saccharomyces cerevisiae. Micro Cell Fact 11(1): 131
Park JH, Lee KH, Kim TY, Lee SY (2007) Metabolic engineering of Escherichia coli for the production of L-
valine based on transcriptome analysis and in silico gene knockout simulation. Proc Natl Acad Sci U S A
104(1 9)7797-7802 doi: 10 .1073/pnas.07026091 04
Patchett ML, Daniel RM, Morgan HW (1991) Characterisation of arginase from the extreme thermophile
'Bacillus caldovelox'. Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology
1077(3):291 -298 doi: http://dx.doi.orq/1 0.1016/01 67-4838(91)90543-9
Rosenberg, Alan H., et al. "Vectors for selective expression of cloned DNAs b T7 R A
polymerase." Gene 56.1 (1987): 125-135.
Scalcinati G, Knuf C, Partow S, Chen Y, Maury J, Schalk M, Daviet L, Nielsen J, Siewers V (2012)
Dynamic control of gene expression in Saccharomyces cerevisiae engineered for the production of plant
sesquitepene a-santalene in a fed-batch mode. Metab Eng 14(2):91-1 03
doi: http://dx.doi.orq/1 0.1 0 16/i.vmben.201 2.01 .007
Shao, Z., Zhao, H. & Zhao, H. DNA assembler, an in vivo genetic method for rapid construction of biochemical
pathways. Nucleic Acids Res. 37, e16 (2009).
Schneider, Jens, and Volker F. Wendisch. "Putrescine production by engineered Corynebacterium
giutamicum." Applied microbiology and biotechnology 88.4 (201 0): 859-868.
Song W, Niu P, Chen X, Liu L (2014) Enzymatic production of l-ornithine from l-arginine with recombinant
thermophilic arginase. Journal of Molecular Catalysis B: Enzymatic 0(0): 1-7
doi: http://dx.doi.orq/1 0.1 0 16/i.molcatb.201 4.09.005
Subhi AL, Diegelman P, Porter CW, Tang B, Lu ZJ, Markham GD, Kruger WD. Methylthioadenosine
phosphorylase regulates ornithine decarboxylase by production of downstream metabolites. J Biol Chem.
2003;278(50):49868-73
Zhan Y, Liu J, Mao P, Zhang H, Liu Q, Jiao Q (2013) Biotransformation of l-ornithine from l-arginine using
whole-cell recombinant arginase. World J Microbiol Biotechnol 29(1 1):21 67-21 72 doi: 10.1 007/s1 1274-01 3-
1382-5
CLAIMS
1. An eukaryotic cell capable of producing L-ornithine, wherein said eukaryotic cell is genetically modified for
attenuated activity of an ornithine carbamyoltransferase.
2 . The eukaryotic cell according to claim 1, wherein said eukaryotic cell is genetically modified for attenuated
expression of a gene encoding said ornithine carbamyoltransferase in said eukaryotic cell.
3 . The eukaryotic cell according to claim 2, wherein said eukaryotic cell has a native promoter of said gene
encoding said ornithine carbamyoltransferase replaced by a weak constitutive promoter.
4 . The eukaryotic cell according to claim 3, wherein said eukaryotic cell has a native promoter of the gene
ARG3 replaced by a promoter of the gene KEX2.
5 . The eukaryotic cell according to any of the claims 1 to 4, wherein said eukaryotic cell is genetically modified
by deletion or disruption of a gene encoding an L-ornithine transaminase.
6 . The eukaryotic cell according to claim 5, wherein said eukaryotic cell is genetically modified by deletion or
disruption of the gene CAR2.
7 . The eukaryotic cell according to any of the claims 1 to 6, wherein said eukaryotic cell is genetically modified
for enhanced L-ornithine biosynthesis from a-ketoglutarate.
8 . An eukaryotic cell capable of producing L-ornithine, wherein said eukaryotic cell is genetically modified for
enhanced L-ornithine biosynthesis from a-ketoglutarate.
9 . The eukaryotic cell according to claim 7 or 8, wherein said eukaryotic cell is genetically modified for
cytosolic L-ornithine biosynthesis from a-ketoglutarate.
10 . The eukaryotic cell according to claim 9, wherein said eukaryotic cell comprises at least one of gene
selected from a group consisting of a gene encoding a cytosolic glutamate N-acetyltransferase, a gene encoding
a cytosolic N-acetylglutamate kinase, a gene encoding a cytosolic N-acetyl-garnma-gSutamy!-phosphate
reductase, a gene encoding a cytosolic acetylornithine aminotransferase and a gene encoding a cytosolic
ornithine acetyltransferase
11. The eukaryotic cell according to claim 10 wherein said eukaryotic cell comprises the genes argA and
argBfc from Escherichia c i and the genes argCca, argDcg and argJcg from Coryne ac e n giuta icu .
1 . The eukaryotic cell according to claim 7 or 8, wherein said yeast is genetically modified for overexpression
of at least one gene selected from a group consisting of a gene encoding an N-acetyl-garnma-gSutamyS-phosphate
reductase, a gene encoding a mitochondrial ornithine acetyltransferase, a gene encoding an acetylornithine
aminotransferase and a gene encoding an a ety g u ate synthase.
13 The eukaryotic ce l according to claim 1 , wherein said yeast is genetically modified for overexpression of
the genes ARG5, 8ARG7 ARG8 and ARG2.
14 . The eukaryotic cell according to any of the claims 7 to 13, wherein said eukaryotic cell is genetically
modified for overexpression of at least one gene selected from a group consisting of a gene encoding a L-ornithine
transporter, a gene encoding a L-glutamate transporter and a gene encoding NADP-^dependent glutamate
dehydrogenase.
15 . The eukaryotic cell according to claim 14, wherein said eukaryotic cell is genetically modified for
overexpression of the genes ORT1, AGC1, GDH1.
16 . The eukaryotic cell according to any of the claims 1 to 15, wherein said eukaryotic cell is genetically
modified for enhanced a-ketoglutarate biosynthesis.
17 . An eukaryotic cell capable of producing L-ornithine, wherein said eukaryotic cell is genetically modified for
enhanced a-ketoglutarate biosynthesis.
18. The eukaryotic cell according to claim 16 or 17, wherein said eukaryotic cell is genetically modified for
attenuated glucose uptake.
19. The eukaryotic cell according to any of the claims 16 to 18, wherein said eukaryotic cell is genetically
modified for overexpression of a gene encoding a glucose transporter regulator protein.
20. The eukaryotic cell according to claim 19, wherein said eukaryotic cell is genetically modified for
overexpression of the gene MTH1 or the gene ΜΤΗ 1-∆ Τ, wherein said gene MTH1-AT \S an internal deletion
version of said gene MTH1.
21. The eukaryotic cell according to any of the claims 1 to 20, wherein said eukaryotic cell is genetically
modified for overexpression of a gene encoding an arginase.
22. The eukaryotic cell according to claim 21, wherein said eukaryotic cell is genetically modified for
overexpression of the gene CARL
23. The eukaryotic cell according to any of the claims 1 to 22, wherein said eukaryotic cell is genetically
modified by:
having a native promoter of the gene ARG3 replaced by a promoter of the gene KEX2;
deletion or disruption of the gene CAR2;
overexpression of the genes ORT1, AGC1, GDH1;
expression of the genes argA and argB from Escherichia c and the genes argCcg,. argDcg and argJcg
from Corynebadehum gi ta icu and
overexpression of the gene ΜΤΗ 1-∆ Τ.
24. The eukaryotic cell according to claim 23, wherein said eukaryotic cell is genetically modified for
overexpression of the gene CARL
25. The eukaryotic cell according to any of the claims 1 to 24, wherein
said eukaryotic cell is capable of producing a polyamine selected from the group consisting of putrescine,
spermidine and spermine; and
said eukaryotic cell is genetically modified for overexpression of a gene encoding ornithine decarboxylase
(ODC) and/or attenuated activity of ODC antienzyme.
26. The eukaryotic cell according to claim 25, wherein said eukaryotic cell is genetically modified for
overexpression of the gene SPE1 and deletion or disruption of the gene OAZ1.
27. The eukaryotic cell according to any of the claims 1 to 26, wherein
said eukaryotic cell is capable of producing a polyamine selected from the group consisting of spermidine
and spermine; and
said eukaryotic cell is genetically modified for overexpression of a gene encoding an S-adenosylmethionine
decarboxylase and/or a gene encoding a spermidine synthase.
28. The eukaryotic cell according to claim 27, wherein said eukaryotic cell is genetically modified for
overexpression of the genes SPE2 and SPE3.
29. The eukaryotic cell according to any of the claims 1 to 28, wherein
said eukaryotic cell is capable of producing a polyamine selected from the group consisting of spermidine
and spermine; and
said eukaryotic cell is genetically modified for expression of a gene encoding a carboxynorspermidine
dehydrogenase and/or a gene encoding a carboxynorspermidine decarboxylase.
30. The eukaryotic cell according to claim 29, wherein said eukaryotic cell is genetically modified for expression
of:
iv) the genes Cj0172c and ' 5 5c fro m Capylobacter jejuni;
the genes VC1624 and VC1623 from Vibrio cholera; or
vi) the genes Lys1 and nspC from Bacteriodes uniformis.
3 1 . The eukaryotic cell according to any of the claims 1 to 30, wherein
said eukaryotic cell is capable of producing spermine; and
said eukaryotic cell is genetically modified for overexpression of a gene encoding a spermine synthase.
32. The eukaryotic cell according to claim 31, wherein said eukaryotic cell is genetically modified for
overexpression of the gene SPE4.
33. The eukaryotic cell according to any of the claims 25 to 32, wherein said eukaryotic cell is genetically
modified for overexpression of a gene encoding a polyamine transporter.
34. The eukaryotic cell according to claim 33, wherein said eukaryotic cell is genetically modified for
overexpression of at least one gene selected from the group consisting of TP01, TP02, TP03, TP04 and TP05.
35. The eukaryotic cell according to any of the claims 1 to 34, wherein said eukaryotic cell is a fungal cell,
preferably a yeast cell.
36. The eukaryotic cell according to claim 35, wherein said yeast cell is selected from a genus consisting of
the group consisting of Saccharomyces, Cryptococcus, Trichosporon, Zygosaccharomyces, Debaromyces, Pichia,
Schizosaccharomyces, Trigonopsis, Brettanomyces, Aureobasidium, Nadsonia, Lipomyces, Torulopsis,
Kloeckera, Phaffia, Rhodotomla, Candida, Hansenula, Kluyveromyces, Yarrowia, and Schwanniomyces,
preferably from the group consisting of Saccharomyces, Yarrowia, Zygosaccharomyces, Kluyveromyces and
Pichia spp, more preferably said yeast cell is selected from the group consisting of Saccharomyces cerevisiae,
Saccharomyces boulardii, Zygosaccharomyces bailii, Kluyveromyces lactis, Yarrowia lipolytica,
Schizosaccharomyces pombe, Hansenula anomala, Candida sphaerica, and Schizosaccharomyces
malidevorans, such as Saccharomyces cerevisiae.
37. A process for production of L-ornithine, said process comprising cultivating a eukaryotic cell according to
any of the claims 1 to 24, 35, 36 in the presence of a carbon source.
38. A process for production of a polyamine selected from the group consisting of putrescine, spermidine and
spermine, said process comprising cultivating a eukaryotic cell according to any of the claims 25 to 36 in the
presence of a carbon source.
39. The process according to claim 37 or 38, wherein said carbon source is selected from a group consisting
of hemicelluloses, celluloses, pectines, rhamnose, fucose, maltose, galactose, maltodextrines, ribose, ribulose,
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